Molecular Mechanism for the Biosynthesis of Antifungal HSAF and Antibacterial WAP-8294A2 by Chen, Haotong
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Student Research Projects, Dissertations, and
Theses - Chemistry Department Chemistry, Department of
Spring 5-2015
Molecular Mechanism for the Biosynthesis of
Antifungal HSAF and Antibacterial WAP-8294A2
Haotong Chen
University of Nebraska-Lincoln, haotong.chen@huskers.unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/chemistrydiss
Part of the Chemistry Commons
This Article is brought to you for free and open access by the Chemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Student Research Projects, Dissertations, and Theses - Chemistry Department by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Chen, Haotong, "Molecular Mechanism for the Biosynthesis of Antifungal HSAF and Antibacterial WAP-8294A2" (2015). Student
Research Projects, Dissertations, and Theses - Chemistry Department. 54.
http://digitalcommons.unl.edu/chemistrydiss/54
	  	  
	  
MOLECULAR MECHANISM FOR THE BIOSYNTHESIS OF ANTIFUNGAL 
HSAF AND ANTIBACTERIAL WAP-8294A2 
 
by 
 
Haotong Chen 
 
A DISSERTATION 
 
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Doctor of Philosophy 
 
Major: Chemistry 
Under the Supervision of Professor Liangcheng Du 
Lincoln, Nebraska 
April, 2015 
 
 
	  	  
	  
MOLECULAR MECHANISM FOR THE BIOSYNTHESIS OF ANTIFUNGAL 
HSAF AND ANTIBACTERIAL WAP-8294A2 
Haotong Chen, Ph.D. 
University of Nebraska, 2015 
Advisor: Liangcheng Du 
Bioactive natural products are a major source of anti-infectives. Many ubiquitous 
inhabitants of soil and water, such as the Gram-negative, prolific producers of natural 
products, Lysobacter, remain largely unexplored. This PhD thesis reports our studies 
of the biosynthetic mechanism for a novel antifungal natural product HSAF and a 
potent anti-MRSA natural product WAP-8294A2. 
In the first chapter, we give a short review of the biosynthesis of polyketides, 
focusing on those which exhibit new biosynthetic features. In subsequent chapters, we 
present original research on the biosynthetic mechanisms of dihydromaltophilin, a 
heat stable antifungal factor (HSAF). HSAF is the main antifungal factor that the 
biocontrol agent Lysobacter enzymogenes produces to fight against fungal pathogens. 
Most interestingly, the genetic feature of HSAF biosynthesis suggests that the same 
polyketide synthase (PKS) module acts not only iteratively, but also separately. In the 
thesis, we demonstrated the in vitro and in vivo production of the polyene tetramate, 
providing direct evidence for this highly unusual iterative polyketide biosynthetic 
mechanism that is likely general for this type of hybrid polyketide-peptides. We also 
investigated four oxidoreductase (OX1-4) genes in the HSAF biosynthetic gene 
cluster, to define the minimal gene cluster required for HSAF biosynthesis. Together, 
the results support a new biosynthetic mechanism: a single set of domains of an 
iterative PKS-NRPS, in cooperating with a cascade of redox enzymes, to synthesize a 
complex and highly modified polycyclic tetramate macrolactam. 
	  	  
	  
The final part of the thesis presents research on WAP-8294A, a complex of at least 20 
cyclic lipodepsipeptides exhibiting remarkable activity against methicillin-resistant 
Staphylococcus aureus (MRSA). All WAP-8294A compounds contain a 3-hydroxy 
fatty acyl chain, varied only in the chain length and branching pattern. The 
mechanism for activating and introducing the 3-hydroxy fatty acid chain into the 
peptide is unclear. We have identified seven putative acyl CoA ligase (ACL) genes 
and generated gene-disruption mutants. We also expressed the genes in E. coli to 
obtain the pure enzymes. Both the in vivo and in vitro results showed that ACL-6 is 
the dominant enzyme responsible for the activation of 3-hydroxyl-7-methyloctanoic 
acid and the subsequent initiation of WAP core structure formation.   
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Chapter 1: Iterative Events in the Biosynthesis of Natural Products by Bacterial 
Type I Polyketide Synthase  
1. Introduction 
Polyketides are a highly diverse group of natural products, which are biosynthesized 
from short acyl-CoA units by polyketide synthases (PKSs)1-3. They represent an 
important source of novel therapeutics. The research of polyketides has led to the 
discovery of an enormous variety of natural products with a wide range of biological 
activities, many of which have found use as new pharmaceuticals, such as antibiotics, 
immuno-suppressants, antiparasitics, hypolipidemics, and anti-tumoral agents4.  
Over the past two decades, the biosynthetic gene clusters for a broad range of PKSs 
have been identified and characterized, and the studies of the structures, mechanisms 
and activities of PKSs have expanded the pool of novel compounds with a great 
diversity of activities through engineered combinatorial biosynthesis5, 6. Thus the 
remarkable versatility and amenability of PKSs make them attractive targets for 
pathway engineering to produce natural product analogues7-12. Bacterial Type I PKSs, 
the best-characterized PKSs, are responsible for creating a significant percentage of 
bioactive natural products13. This group of synthases has a modular organization, and 
each module within the PKS carries out one cycle of polyketide chain elongation 
(thus “non-iterative” in function). It is possible to deduce the core structure of a 
polyketide product from the organization of a typical type I PKS, since there is a 
well-established co-linearity between the number of chain elongations and the number 
of modules14-17. This rule is helpful in the reprogramming and rational redesign of 
novel natural products, which has given natural products a renewed prominence in 
drug discovery programs11, 17. However, more and more counter examples to the 
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co-linearity rule have emerged1, 18, 19. In bacteria, the iterative use of one or more 
modules in a type I PKS has made it challenging to predict the structure of the 
product and to engineer the biosynthetic genes.  
Iteratively used bacterial type I PKSs, which include module stuttering in modular 
PKSs19, bacterial aromatic iterative PKSs20, PUFA PKSs21, 22, enediyne PKSs23-25, and 
the PTM PKS26, 27, give rise to an impressive structural diversity of polyketide 
biosynthetic products, which are hard to deduce from the domain/modular 
arrangement of the biosynthetic machinery28. Little is known about the mechanism of 
iterative modules at the molecular level29, 30. Elucidation of the assembly of iterative 
modules, how they recognize their substrates, and how they function are issues at the 
frontier of natural product research and provide new prospects and inspirations for 
novel compound discovery and engineering. The following is a brief review of 
examples of module iterative phenomena in bacterial type I PKSs and mechanistic 
studies of their processes. 
1-1. Classification of PKSs 
Nature supplies a large group of polyketides with highly diverse structures and 
biological activities. Many of these polyketides are medicines or leads for the 
development of anti-infective and anticancer drugs, such as erythromycin 
(antibacterial), ambruticin (antifungal), and daunorubicin (antitumor)4. Despite their 
tremendous diversity in structure and function, polyketides share a common 
biosynthetic mechanism, as the carbon backbones are biosynthesized from short 
acyl-CoA precursors by a sequential condensation catalyzed by polyketide synthase 
(PKS).31 In general, polyketide synthase in charge of selecting, fusing, and processing 
the building blocks consists of individual catalytic domains. The chain initiation and 
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extension substrates are selected and activated by an acyl transferase (AT) domain, 
and transferred to the 4'-phosphopantetheinylated acyl carrier protein (ACP) domain. 
The ketosynthase (KS) domain catalyzes the decarboxylative Claisen condensation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Examples of natural products synthesized by bacterial type I PKSs, which 
are described in this review.  
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between the substrate and the growing polyketide, forming a carbon-carbon covalent 
bond between the alpha carbon of the extender unit and the thioester carbonyl of the 
ACP-bound acyl chain. While a PKS requires a minimum of these three domains to 
function, other commonly present domains are the ketoreductase (KR), 
dehydrogenase (DH), and enolreductase (ER), which reduce the β-keto group into a 
fully saturated acyl chain. Most PKSs vary in the use of these reductive steps in the 
processing of the β-keto group, thus generating a greater diversity and complexity of 
polyketide products.  
The classification of PKSs is based on the structural organization of PKS domains. In 
type I PKSs, a single large polypeptide chain houses multiple different active sites 
(domains) capable of catalyzing different reactions. Such PKSs are found in both 
bacteria and fungus. Type II PKS are usually found in bacterial systems, assign the 
different enzymatic activities of the polyketide synthesis to separate dissociable 
proteins. The majority of known type II PKS metabolites are aromatic products, 
although exceptions are known32. Type III PKSs utilize acyl-coenzyme A (CoA) 
thioesters directly, rather than depending on extender units tethered to an acyl carrier 
protein (ACP). These systems also produce aromatic metabolites, but are mainly 
distributed in the plant kingdom, while seldom occurring in bacteria33. While these 
classifications of PKSs are useful generalizations, nature does not limit itself to only 
three rigidly-defined methods for generating polyketide metabolites34. We will limit 
our discussion to examples in which type I modular PKSs synthesize polyketides 
behave in a non-canonical iterative pattern, thus combining two traits once thought to 
be mutually exclusive to fungal or to bacterial systems. 
1-2. Classification of type I PKSs. 
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Type I PKSs are often classified into two major groups: the iterative (fungal) type I 
PKSs and modular (bacterial) type I PKSs. In iterative I PKSs (iPKSs), consist of one 
multienzyme protein, containing only a single module subdivided into various 
extending and tailoring domains, which is nevertheless capable of conducting 
multiple rounds of chain extension and β-keto processing. The varied reduction level 
of the β-keto during each round of elongation is the most intriguing feature of this 
PKS type35-37. These types of iPKSs are largely confined to fungal systems, thus will 
not be discussed in this review. Modular type I PKSs, in contrast, include multiple 
sequential modules, each of which contain the needed extending and tailoring 
domains, and operate in a modular fashion with each module being responsible for 
only one round of chain elongation and subsequent β-keto processing before passing 
the nascent polyketide is passed on to the downstream module, which carries out 
another round of chain extension and processing. Examples of such modular type I 
PKSs include those responsible for the biosynthesis of the macrolides such as 
erythromycin38, 39 and avermectin40. These bacterial type I PKSs thus carry out each 
successive chain extension cycle by a different set of active sites housed in separate 
modules, and one or more such modules may exist on each multifunctional 
polypeptide. Importantly, in most modular type I PKSs, each active site is used only 
once. This linear mechanism used to be regarded as general for the biosynthesis of 
polyketides by type I PKSs in bacterial systems.  
The repeated emergence of unusual type I PKSs has expanded the repertoire of PKSs. 
Although all of them have the basic modular structures, the unusual type I PKSs often 
have intriguing arrangements of the functional domains and exhibit a phylogenetic 
distance from either iterative or modular PKSs, making them fall into five new 
subgroups, including bacterial aromatic iPKS, polyunsaturated fatty acid (PUFA) 
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synthases, enediyne, polycyclic tetramate macrolactams (PTM) and AT-less type I 
PKSs41, 42. The structures of typical natural products of each group are showed in 
Figure 1-1. 
1-3. Phylogenic study of type I PKSs. 
 
 
 
 
 
 
 
 
Figure 1-2. Phylogenetic analysis of different types of PKSs based on KS domains. 
Enzymes and their GenBank accession numbers are listed as follows: bacterial 
aromatic iPKS (3 sequences, including AziB for Azinomycin biosynthesis, 
ABY83164.1; NcsB for Neocarzinostatin biosynthesis, AAM77986.1; SACE_5532 
for Mellein biosynthesis, YP_001107644.1). PTM type iPKSs (3 sequences, including 
PKS for HSAF biosynthesis, EF028635.2; PKS from Streptomyces albus J1074, 
ABYC01000481; PKS from Streptomyces griseus, AP009493); modular PKSs (3 
sequences, including PimS1 module 1 for Pimaricin biosynthesis, CAC20931.1; 
MonAI: module 1 for Monensin biosynthesis, AAO65796.1; EryA1: module 2 for 
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Fum1p for Fumonisin biosynthesis, AAD43562.2; LovF for Lovastatin biosynthesis, 
AAD34559.1; MkB for Monacolin biosynthesis, ABA02240.1), NR-PKS (3 
sequences, including PksA for Aflatoxin biosynthesis from Aspergillus. flavus, 
AAS90093.1; PKS1 for Melanin biosynthesis from Colletotrichum lagenaria, 
BAA18956.1; PKS1 for Melanin biosynthesis from Glarea lozoyensis, AAN59953.1); 
enediyne synthases (3 sequences, including SgcE for C-1027 biosynthesis, 
ZP_11383500.1; MdpE for Maduropeptin biosynthesis, AAQ17110.2; NcsE for 
Neocarzinostatin biosynthesis, AAM78012.1) and PUFA synthases (3 sequences, 
including PfaA for EPA biosynthesis from Photobacterium profundum, AAL01060.1; 
Orf8 for DHA biosynthesis from Moritella marina, BAA89382.2; OrfA for EPA and 
DHA biosynthesis from Schizochytrium AAK72879.2). Numbers above branches 
indicate bootstrap values (1000 replicates) of the major clades. Similar sequences 
were aligned with ClustalW and the tree shown was generated using the MEGA 5.0).  
 
Phylogenetic studies20, 43 have investigated the evolutionary relation and catalytic 
diversity of PKSs. The bacterial aromatic iterative PKSs and PTM- type PKSs make 
up two independent clades that lie close to each other and sister to modular PKSs, but 
are phylogenetically distant from the clade containing two other types of bacterial 
iPKSs, that is, enediyne PKSs and PUFA synthases, and the clade containing fungal 
NR-PKSs and HR-PKSs (Figure 1-2). The phylogenetic differences between the 
subgroups in type I PKSs helps understand the relationships between these type I 
PKSs, and has given rise to the development of a rapid PCR approach to specifically 
access the genes encoding these enzymes44, 45.  
1-4. Non-canonical bacterial type I PKS 
Bacterial type I PKSs were originally thought to be rigidly modular and co-linear with 
the core structure of final products, so that the core structure of an unknown 
compound produced by this type of PKS should be capable of deduction from 
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bioinformatics analysis of PKS genes. Due to the high level of programming, type I 
PKS systems have the potential to be engineered to make novel analogues of known 
metabolites. Through biosynthetic engineering, novel compounds have been accessed 
by re-programming type I PKS systems in a number of ways. Among other 
experiments, loading modules have been swapped, modules have been deleted or 
inserted, domains swapped or inactivated, and domains reprogrammed to impart new 
functions, among other experiments46.  
However, there are many deviations from the co-linearity in PKS systems have been 
discovered in recent years. Two major reasons contribute to the loss of co-linearity: 
non-canonical domains and non-canonical modules. The phenomenon of 
non-canonical domains includes additional domains, loss of specificity of AT 
domains, absence of domains for required functions, and novel domain functions and 
domain organization47. For example, the newly discovered branching domain 
acetylates an enzyme-bound enoyl moiety by means of a Michael-type conjugate 
addition, resulting in a β-branch instead of an elongated backbone in rhizoxin 
biosynthesis (Figure 1-3B)48. Trans domain activities refer to discrete enzymes which 
act only at specific points during the synthesis of nascent acyl chains, separate from 
the usual modifying activities. Examples are trans AT in AT-less PKS system such as 
leinamycin synthase (Figure 1-3B)41, 49, a discrete KR domain (antM) in the 
biosynthesis of antimycins50, and a discrete DH domain in the biosynthesis of 
phoslactomycin 51, 52. Structures of the compounds discussed above are listed in 
Figure 1-1. 
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Figure 1-3. Examples of canonical bacterial type I PKSs and non-canonical bacterial 
type I PKS. KS, ketosynthase; AT, acyltransferase; DH, dehydratase; KR, 
ketoreductase; ACP, acyl carrier protein; TE, thiolesterase; C-MeT, 
C-methyltransferase; ER, enoyl reductase; B, branching domain. 
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The non-canonical domains affect the co-linearity mainly in the modification of the 
backbone, such as generating unpredictable reduction levels of the β-keto group. But 
the non-canonical modules sometimes result in changing the size of the backbone in 
the final products. The most frequent of such aberrations are the skipping of various 
modular PKS single domains, or sometimes of entire modules; conversely, individual 
modules may be used more than once, giving rise to the so-called “module stuttering”, 
an example of a bacterial iterative PKS. Such events lead to inconsistency between 
the genetic organization of the biosynthetic gene cluster and its corresponding 
proteins, and its ultimate PKS metabolite.  
A PKS which skips over modules usually does so in “programmed skips”, passing 
over extraneous functional domains or modules in a PKS for which there is no 
obvious need in the biosynthesis of the corresponding polyketide; one such case is 
that of the similar KS-ACP bi-domain module in the biosynthesis of mupirocin42. 
There is also a trace amount of truncated derivatives produced during the biosynthesis 
of avermectin and epothilone (Figure 1-3B)53, 54, suggesting that the truncated 
compounds are produced by the aberrant bypass of one or other module during 
biosynthesis. The reveromycin-producing PKS is one example where the genetic 
organization of the biosynthetic gene cluster and the corresponding proteins are not 
co-linear55. The analysis of the reveromycin PKS shows that it is possible that after 
translation, RevC protein (module 1-3), associates with RevA (module 4-6) instead of 
RevD, whose gene is located next to and downstream of RevC to bring the set of 
contiguous domains together to form functional modules. Therefore, even when the 
PKS genes are not present on the chromosome in a co-linear arrangement, the gene 
products form a specific head-to-tail complex through which the polyketide chain is 
processed in a programmed fashion and biosynthesis occurs in a co-linear fashion.  
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Iterative use of one or more modules will often result in longer polyketide chains than 
those predicted by the co-linear model (Figure 1-3B). This “module stuttering” 
composes a large group of non-canonical bacterial type I PKS. Beside those with a 
special domain organization, which already fall into novel subclasses of type I PKSs 
(bacterial aromatic iPKS, polyunsaturated fatty acid (PUFA), enediyne PKSs), there 
are still many extraordinary examples which lie beyond any existing classifications. 
In the following sections, I summarize the iteration events known to occur in bacterial 
type I PKSs and discuss the proposed mechanisms behind this phenomenon. 
2. Iteratively used bacterial type I PKS  
Iterative type I PKSs can be considered in two categories: entirely iterative PKSs 
(“fungal” type iPKS) and partially iterative PKSs (which contain stuttering modules).  
2-1. Entirely iterative bacteria PKSs 
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Figure 1-4. Domain organization of bacterial type I iPKSs and represented 
compounds produced by these synthases. Domain organizations of iterative type I 
PKSs, including aromatic iPKS, enediyne PKS, PUFA synthase and PTM PKS in 
bacteria. ACPn, multiple ACPs; PPTase, phosphopantetheinyl transferase. 
 
2-1-1. Bacterial aromatic iPKSs  
Most aromatic compounds produced by bacteria were believed to be synthesized by 
type II PKSs, until the first iterative type I PKS, AviM, was cloned in 1997 (Figure 
1-4a)56. Heterologous expression of AviM and the biosynthesis of ordellinic acid in 
vitro confirmed that AviM is an iterative type I PKS that is able to catalyze aromatic 
polyketide synthesis. CalO5, which is responsible for biosynthesis of calicheamicin 
(Figure 1-4a), was successfully characterized to be another iterative type I PKS in 
bacteria25, 57. Besides the monocyclic aromatic polyketides, there are iterative type I 
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PKSs that also can generate higher-order aromatic polyketides, such as NcsB, which 
catalyze the formation of a naphthalinic acid moiety in neocarzinostatin biosynthesis58. 
So far, the known bacterial aromatic iPKSs are associated with the biosynthesis of 
chlorothricin44, maduropeptin59, polyketomycin60, pactamycin61, tiacumicin B62, 
azinomycin B63 and (R)-mellein64.  
Bacterial aromatic iPKSs are typically organized in the order of 
KS-AT-DH-(KR)-ACP (Figure 1-4a), and share high homology with each other, 
which is very similar to that of modular type I PKSs. Although the bacterial iPKSs are 
also highly homologous to fungal 6-MSA synthases37, the absence of a C-methylation 
(CMeT) and enoylreductase (ER) domains is the most notable difference, suggesting 
a convergent evolution of PKSs to produce similar aromatic cores.  
Bacterial aromatic iPKSs contributes to the diversity of polyketides generally through 
their unusual domain functions, different mechanisms for polyketide off-loading and 
post-synthesis modifications. For instance, most of the aromatic PKS KR domains 
contain a motif similar to the Leu-Asp-Asp motif of B-type KRs, suggesting that all 
the KR domains of bacterial aromatic iPKSs specifically generate D-hydroxyl group 
by reduction of the β-keto group (Figure 1-5B)65, 66. But different KR domains vary 
the hydroxylation pattern, generating different cyclized rings (5-methyl-1- NPA for 
AziB and 2-hydroxyl-5-methyl-1-NPA for NcsB) (Figure 1-5A). An unusual 
off-loading mechanism was discovered in bacterial aromatic iPKSs. In the 
biosynthesis of chlorothricin, pactamycin, avilamycin, tiacumicin B, and 
calicheamicin, a dedicated AT is utilized to release the polyketides products from 
PKSs (Figure 1-5C)67-70.  
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Figure 1-5. Bacterial aromatic iPKS-catalyzed reactions and the off-loading 
mechanism in the biosynthesis of avilamycin. The selective keto-reduction patterns 
are highlighted in red. ATs are represented by red rectangles.  
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relatively simple system for understanding the rationale behind the catalysis achieved 
by these impressive enzymes. Further understanding of these domains in bacterial 
aromatic iPKSs will hopefully facilitate the alterations of the functionalities on the 
aromatic polyketides, opening the door to bioengineering studies and the production 
of novel natural products with improved biological activities. 
2-1-2. PUFA  
Polyunsaturated fatty acids (PUFAs) are essential to human health and nutrition. 
PUFAs contain multiple cis double bonds and have been identified outside of the 
eukaryotic realm in various marine bacteria. A gene cluster pfa was cloned into 
Escherichia coli, from a Shewanella sp., and was found to be responsible for 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) biosynthesis (Figure 
1-4b)22. Five open reading frames were subsequently found to be the minimal gene set 
for PUFA biosynthesis71. Based on analysis of PUFA iPKSs, five to nine tandem 
ACP domains are present in the iPKSs, besides basic domain composition of KS, AT, 
KR, and DH (Figure 1-4b).  
After heterologous expression the PUFA iPKS, (pfaABCDE) from S. japonica in E. 
coli, together with a series of in vitro and in vivo characterizations of these iPKS 
proteins, Jiang and co-workers speculated that each of the bioinformatically predicted 
ACPs can be phosphopantetheinylated by the PPTase at the N-terminus both in vitro 
and in vivo72. Each of the tandem ACPs was functionally equivalent for PUFA 
biosynthesis, but the number of functional ACPs correlated directly to PUFA titers.  
Further efforts will be made to rigorously dissect PUFA iPKSs from broader 
microbial PUFA producers.  
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2-1-3. Enediyne biosynthesis  
The enediyne are a family of antibiotics containing a strained ring system (9 or 10 
membered), which are extremely cytotoxic (Figure 1-4c)73.  
The biosynthetic gene clusters for two such metabolites, the chromoprotein antibiotic 
C-102723 and calicheamicin25, have been identified and published, and the enediyne 
core of these metabolites was believed to be synthesized by a type I PKS. Ben Shen 
and co-workers cloned a gene cluster from Streptomyces globisporus containing the 
PKS gene sgcE,23 part of the gene cluster responsible for the biosynthesis of the 
model nine-membered enediynes C-1027. The enediyne PKS sgcE contains six 
domains (Figure 1-4c). The region between AT and KR was proposed to be an ACP, 
which is a quite unusual location for an ACP domain. More interestingly, the 
C-terminus region of the PKS was predicted to be a phosphopantetheinyl transferase 
(PPTase) domain, loading the phosphopantetheinyl arm of CoA onto the ACP. This is 
an extremely rare event and probably unique to enediyne PKSs. Overall, the enediyne 
PKS shows the greatest homology to the PUFA PKSs, and like them they lack ER 
domains.  
The involvement of SgcE in C-1027 biosynthesis was confirmed by gene inactivation 
and complementation: a ΔsgcE mutant eliminated the production of C-1027, and 
overexpression of SgcE in ΔsgcE restored C-1027 production23. This iPKS could 
iteratively catalyze the assembly of a linear polyunsaturated intermediate, which was 
further processed by a series of desaturations to furnish the two alkyne groups and 
cyclized to afford the enediyne core. Indeed, a group of five to ten genes is flanking 
the sgcE PKS gene, which are highly conserved and homologous to the 
oxidoreductases or proteins of unknown functions that are only associated with 
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enediyne biosynthesis, hinting at the possible novel chemistry involved in the 
synthesis of these natural products. 
CalO5, which is also discussed above, catalyzes the biosynthesis of the orsellinic acid 
(OSA) core (Figure 1-4c). The gene was cloned together with another PKS encoded 
gene calE8 within the same cluster from Micromonospora echinospora sp. 
calichensis25. The resulting compound is calicheamicin, which is a model for the 
10-membered enediyne antibiotics. The involvement of CalE8 in calicheamicin 
biosynthesis was also confirmed by gene inactivation. The domain organization of 
calE8 is homologous to sgcE. The observed similarity between SgcE and CalE8 
clearly suggests a common polyketide pathway for the biosynthesis of both nine- and 
ten-membered enediynes. The biosynthetic mechanism of calicheamicin is very 
similar to that of C-1027; the CalE8 PKS catalyzes the biosynthesis of a nascent 
polyunsaturated intermediate in an iterative process. Modifications by the associated 
oxidoreductases within the gene cluster then form an enediyne core intermediate. 
SgcE and CalE8, therefore, represent a novel family of iterative type I PKSs, 
establishing a new paradigm for enediyne biosynthesis58, 74. 
The discovery of this type of biosynthetic mechanism led to a PCR-based approach to 
access the enediyne PKS loci and its associated redox genes75. The highly 
programmed biosynthetic mechanism suggested the bioengineering potential in 
generating new enediynes.  
2-1-4. PTM iPKS  
Polycyclic tetramate macrolactams are a group of compounds that have recently been 
shown to be produced by a variety of bacterial species (Figure 1-4d)27. A combination 
of small molecule chemistry, biosynthetic analysis, and genome mining in diverse 
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bacteria led to the recognition of this group of compounds as a new class of NPs with 
distinct structure and novel modes of action. The most striking feature of PTM 
biosynthesis is that there is only one single-module PKS-NRPS hybrid gene in the 
biosynthetic gene clusters 76. This feature suggests that the single-module PKS 
responsible for the synthesis of 76the PTM polyketide moieties is not only iterative, 
but also capable of catalyzing the biosynthesis of two separate polyketide chains and 
linking them to the amino acid activated by the NRPS module. 
The hybrid PKS-NRPS for PTM biosynthesis has a typical modular domain 
organization, including KS-AT-DH- KR-ACP for the PKS portion and C-A-PCP-TE 
for the NRPS portion (Figure 1-6). There is no obvious remnants of an inactive 
enoylreductase (ER°) domain or a methyltransferase (CMeT) domain, as seen in 
several iterative fungal PKS-NRPS with the similar organization, or other types of 
batcerial iPKSs. Although this type of iterative PKS-NRPS is commonly seen in fungi, 
it was not thought to be common in bacteria until recent years. Phylogenetic analyses 
showed that there is a close relationship between PTM iPKSs and bacterial aromatic 
iPKSs, rather than fungal iPKSs (Figure 1-6).  
The heat–stable antifungal factor (HSAF), which was isolated from the 
Gram-negative bacterium Lysobacter enzymogenes, exhibits potent inhibitory 
activities against a wide range of fungi, including the life-threatening human pathogen 
Aspergillus fumigatus77-79. Like other bacterial PTM biosynthetic gene clusters, the 
HSAF biosynthetic gene cluster contains only a single PKS-NRPS and the PKS 
contains only a single module, although the HSAF scaffold is apparently derived from 
two separate hexaketide chains along with an ornithine residue76-79. This suggests that 
the same PKS module would act not only iteratively, but also separately, in order to 
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construct and link the two different hexaketide chains with the NRPS-activated 
ornithine to form the characteristic PTM scaffold. We heterologously expressed the 
HSAF biosynthetic gene cluster in Streptomyces host, in which the native PKSs have 
been deleted, and the expected HSAF analogs have been detected and isolated. We 
also demonstrated the iterative polyketide biosynthetic mechanism in vitro using 
purified PKS and NRPS proteins26. 
 
 
 
 
 
 
 
 
 
Figure 1-6. Proposed biosynthetic mechanism for HSAF. 
 
In the in vitro reaction, the hexaketide polyene was the only detected intermediate. 
The results support that the single-module PKS is indeed an iterative PKS, which 
catalyzes five cycles of chain elongation in polyketide biosynthesis. The timing of the 
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second hexaketide chain biosynthesis and transfer is also interesting (Figure 1-6). The 
second hexaketide chain is synthesized and transferred right after the fifth cycle of 
polyketide chain elongation, in which the newly formed β-keto group of the second 
hexaketide chain has not been processed by the KR domain and DH domain. All of 
PTM natural products hitherto discovered retain this unprocessed β-keto group in the 
final structure (HSAF structure, Figure 1-6). The determining factor for this timing is 
not known, but is possibly related to the tailoring redox enzymes that are proposed to 
cooperate with the PKS-NRPS in elaborating the PTM scaffold. 
Recently, the Gulder group reported heterologous expression of the ikarugamycin 
biosynthetic gene cluster in E. coli80, and the Zhang group reported the enzymatic 
mechanism for formation of the inner 5-memebered ring and demonstrated the 
polyketide origin of the ikarugamycin skeleton81. Ikarugamycin is a 
Streptomyces-derived PTM which has a 5,6,5-tricyclic system (Figure 1-4c). Both the 
Gulder and Zhang groups showed that a three-gene cluster is sufficient for 
ikarugamycin biosynthesis. 
In light of the huge number of uninvestigated PTM-type gene clusters in databases, 
we believe our studies will facilitate research in a new area of iterative bacterial type I 
polyeketides. The understanding of the iterative mechanism could be used to guide 
biosynthetic engineering efforts. Knowledge of these biosynthetic mechanisms may 
also transfer to the exploration and discovery of new bioactive NPs from other 
Lysobacter species and allow optimization of the yield, structure, and activity of the 
Lysobacter anti-infectives. 
2-2. Partially iterative bacteria PKSs. 
The iteration pattern in entirely iterative bacterial type I PKSs is similar to that in 
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single-module fungal iPKSs, in which the iteration events occur in only one complete 
PKS module. But in bacterial modular PKSs, the iteration events can happen within 
only one or two modules out of many in the giant assembly line. “Module stuttering” 
is the term used to describe the iterative use of only one module in a multi-modular 
PKS, and is usually implicated when the number of modules present in a PKS is 
fewer than the number of condensation events required for complete biosynthesis of 
the corresponding polyketide47. In recent years, many examples of module stuttering 
have been reported in the biosynthesis of polyketides. Stuttering can be either aberrant 
or programmed.  
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Figure 1-7. Mechanism of modular stuttering. 
 
2-2-1. Unimodular iterations 
In the biosynthesis of erythromycin A in S. erythraea, the detection and isolation of 
minor metabolites (Figure 1-7) in the fermentation broth of S. erythraea strain No. 5 
revealed the first example of how a processive and co-linear modular PKS can operate 
in an iterative fashion in an aberrant manner29. This iteration is considered as aberrant 
because of the trace amounts of the iterative products, as native modular PKSs 
generally exert a rigorous control over the chain length. 
Structural elucidation of the final product indicated that the iteration event happened 
during the fourth chain extension (Figure 1-7A). Such a homologation reaction would 
require the normal pentaketide product of module 4, attached to ACP4 (DEBS2), to 
be transferred back onto the active site cysteine residue of the KS4 domain of the 
same module, rather than being processed onto the downstream KS5 domain of 
DEBS3 (Figure 1-7A). A second, module 4-catalyzed chain extension cycle would 
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occur, producing a novel hexaketide chain attached to the ACP4 (DEBS2). This new 
hexaketide intermediate would be transferred to the KS5 (DEBS3) domain and the 
elongation process would then progress in the normal manner to give a ring-expanded 
octaketide product. The explanation for this aberrant stuttering is that the location of 
the module 4 allows the iteration event to occur before the transfer of the pentaketide 
intermediate to the next module. But this event only happened occasionally.  
The same biosynthetic stuttering has also been found in epothilone PKS, which 
represents the 18-membered macrolactones30. Both of the module 5 and module 6 
could be iteratively used, resulting in 6 different byproducts, based on different 
substrate selectivity of AT domains. The diversity of the iterative by-products 
indicated that the iteration events could happen to different modules within the same 
assembly line.  
Apart from the occasional and unpredictable aberrant stuttering event in Type I 
bacterial PKS biosynthesis, most iterative PKS events are tightly controlled and 
apparently have developed during the evolution of the assembly lines. A number of 
programmed iterative events in Type I modular PKS that correspond to a series of 
natural products have been identified. The best studied and classic examples for the 
programmed iterative use of a type I PKS module are the stigmatellin, aureothin (two 
iterations each), and borellidin (three iterations) pathways (Figure 1-7A).  
As an aromatic myxobacterial electron transport inhibitor, stigmatellin was isolated 
from the myxobacterium Stigmatella aurantiaca32. By analysis of the structure and 
gene cluster, Muller and co-workers believed that there must be 3 more malonyl-CoA 
units added to the backbone by two modules, StiH or StiJ (Figure 1-7A)32, 82. This 
stuttering is different from the ring expansion in erythromycin biosynthesis, since 
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stigmatellin is the only product observed in the culture broth. It strongly suggested a 
dedicated and programmed iterative processing in the PKS assembly.  
The authors speculated thateither StiH or StiJ could be used iteratively, while the 
other worked classically. It’s also possible that this iteration was actually from an in 
trans module outside the gene cluster. To exclude this possibility, the authors mutated 
every PKS-containing gene cluster in the genome of S. aurantiaca83. However, none 
of these mutations eliminated the production of stigmatellin, suggesting that its 
biosynthesis is solely the responsibility of the sti locus, apparently necessitating 
iterative use of the associated PKS. 
The biosynthesis of lankacidin is a very unusual example of the iterative use of a PKS 
module. A module containing KS-DH-CM-ACP1-ACP1-KS-AT spread over four 
proteins is proposed to be iteratively used for the first five condensations84, 85. The 
presence of repeated, virtually identical, ACP domains is the most striking feature, 
suggesting that this module may be involved in iterative use, with twin ACP domains 
having different uses (Figure 1-7A).  
The aureothin PKS also contains a programmed iteratively-used module, which 
represents a favorable model system to investigate the iteration process (Figure 1-7A). 
The iteration module, AurA, not only works iteratively, but also selects the 
p-nitrobenzoate starter unit86. Hertweck and co-workers proposed that the iteration 
happened by retrotransfer of the intermediate from one PKS strand to the opposite 
PKS strand87. In a recent published paper, Hertweck and co-workers confirmed that 
KS1 is in charge of priming the PKS, thus leaving a vacant position for the 
retrotransfer of the diketide. KS2 functions as a gatekeeper that controls the chain 
length of polyketide. The substitution of module 1 of AurA with the avemectin 
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module 1 resulted in abolition of iteration, indicating that iteration is completely due 
to aureothin module 1. The deletion of the TE domain enabled the authors to track the 
intermediates produced by aur PKS. The single AurA, which could catalyze up to 4 
rounds of iteration, suggested a scenario for rational design of complex polyketides by 
pathway engineering. 
2-2-2. Bimodular iterations 
So far, module stuttering has usually been found to involve only one PKS module. 
However, a novel bimodular iteration was unraveled in 200888. A protein involved in 
the biosynthesis of a phosphoglycolipid called mannosyl-β-1-phosphomycoketide 
(MPM) was proposed to contain two complete sets of modules and has been 
suggested to synthesize mycoketide by five alternating condensations of 
methylmalonyl and malonyl units, using an iterative mode of catalysis (Figure 1-7). 
The chemical structure of mycoketide contains branching at every alternate ketide 
unit, suggesting an alternative use of two modules wherein one module would 
condense a branched C3 ketide unit and the next would add a C2 unit. Site mutation 
and radiolabeled experiments confirmed that the AT1 prefers MMCoA while the AT2 
recruits MCoA. 
On the basis of biochemical, computational, mutagenic, analytical ultracentrifugation 
and atomic force microscopy studies, it was proposed that PKS12 protein is organized 
as a large supramolecular assembly mediated through specific interactions between 
the C-and N-terminus linkers. This interaction enables the intermolecular acyl chain 
transfer between two proteins. PKS12 protein thus forms a modular assembly to 
perform repetitive condensations analogous to iterative proteins. This novel 
intermolecular iterative biosynthetic mechanism provides new perspective on the 
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understanding of polyketide biosynthetic machinery and also suggests new ways to 
engineer polyketide metabolites. 
3. Iterative mechanism 
Although more and more non-colinear PKSs have been discovered, the mechanism 
that control the iteration processes in bacterial type I iPKSs has not been clearly 
elucidated89. A possibility could be that iteration is an intrinsic feature of the module 
like FAS and fungal PKSs. Moreover, a “force” coming from the downstream, for 
example, the KS domain which only accepts an intermediate with a particular chain 
length, restricts the upstream module to iterate. A combination of both is also possible. 
Finally, the timing of iteration and extender unit recruiting of the ketosynthase need to 
be coordinated to allow for an unobstructed metabolite flux. 
3-1. Interchenar transfer vs. intrachenar transfer 
The mechanism of fungal iPKS is summarized as: 1) KS domain catalyzes the Claisen 
condensation reaction between the starter and extender units, driven by 
decarboxylation of the extender unit. 2) The intermediate is passed back to the KS 
domain to be extended by another ketide unit, or 3) the finished polyketide chain will 
be released from the enzyme if the polyketide has reached its predetermined length, 
which is unique for each iPKS. The chain length is tightly controlled by a special 
product template (PT) domain in non-reducing fungal PKS36.  
In principle, the iteration might happen under the following scenarios: the 
intermediate is transferred from the ACP domain of one PKS chain to the (a) ACP 
domain on the same PKS chain (‘intrachenar’); (b) ACP domain on the opposite PKS 
chain (‘interchenar’); (c) KS domain upstream on the same PKS chain (‘intrachenar’); 
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or (d) KS domain upstream on the opposite chain (‘interchenar’) (Figure 1-8). 
 
 
 
 
Figure 1-8. Mechanisms of intrachenar transfer and interchenar transfer. 
 
Through targeted domain mutagenesis, cross-complementation experiments, and 
metabolic profiling carried out by Hertweck and co-workers, the mechanism of 
iterative events in a bacterial type I PKS has been addressed87. They revealed that the 
N-terminal ACP is not involved in the iteration process, ruling out an ACP−ACP 
shuttle (Figure 1-9). This is also consistent with the fact that most bacterial iPKSs 
don’t have an N-terminal ACP. Furthermore, an aurA (ΔKS, ΔACP) and aurA (ΔAT) 
heterodimer proved to be nonfunctional, whereas aureothin production was restored in 
a ΔaurA mutant complemented with aurA (ΔKS) − aurA (ΔACP). This finding 
supports that the most likely scenario is (d), a retrotransfer of the biosynthetic 
intermediate from the ACP onto the KS domain located on the opposite polypeptide 
strand. 
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Figure 1-9. Interchenar retrotransfer of intermediate from ACP to KS in aureothin 
biocynthesis. 
 
4. Summary 
PKSs are generally classified into three canonical types according to their domain 
alignment and organizations. With the increasing number of PKSs falling into the 
category of “non-canonical” PKSs, the boundaries between the different types are no 
longer so well defined. These non-canonical type I PKS modules expand the diversity 
of natural product biosynthesis, making engineering and rational design in synthetic 
biology even more complicated. Iteration is likely the most unpredictable event that 
occurs in polyketide biosynthesis. Programmed iteration probably has great potential 
to be engineered to produce polyketides with designed length and modifications. 
The iterations can happen with one module in the giant modular assembly line. The 
number of iterations can be controlled when using specific module, such as the case 
of the AurA module, which can be repetitively used for four times until selected by 
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PKS12 in MPM biosynthesis. Upon switching the AT domain, one might change the 
substrate specificity of the 2 modules, creating the designed backbone for the target 
compounds. Wholly iterative PKSs, including bacterial iPKSs, PTM iPKS, PUFA and 
enediyne biosynthetic PKS, have the potential to provide the core structures of the 
target compounds, which could also be engineered to produce rationally-designed 
complex polyketides. 
However, the mechanistic details for bacterial type I iterations are less understood. 
Although several groups have recently begun to investigate the mechanism of the 
iteration and the timing of retrotransfer, progress still needs to be made to understand 
these processes and to translate the knowledge into rational PKS engineering. At the 
same time, these iterative events reveal that nature recruits “unexpected” mechanisms 
to synthesize novel polyketide natural products. With the rapid growth of genome 
sequence data and in depth biochemical studies of the new PKSs, novel iteration 
mechanisms will continue to emerge. 
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Chapter 2: Iterative Assembly of Two Separate Polyketide Chains by the Same 
Single-module Bacterial Polyketide Synthase in the Biosynthesis of HSAF  
Portions of this chapter were reported (Angewandte Chemie International Edition, 
2014, 53 (29), 7524-7530) and are reproduced with the permission of the publisher26. 
2-1. Background and Significance  
Fungal infections, including meningitis, thrush, ringworm, eye and nail infections, 
lung infections and those topical invasive and allergic diseases in humans and animals, 
represent an increasing threat to public health. According to the latest data, the 
mountain yellow-legged frog population has almost been wiped out in Kings Canyon 
National Park in California due to fungal infections, while 40% of the amphibian 
species have been lost in some areas in Central America, which has led to an 
estimated loss of at least $3.7 billion per year to U.S. agriculture90.
 
 
In agriculture, fungal infections are a major threat to the food supply chain for billions 
of people. In many underdeveloped countries, contamination of crops such as maize 
and groundnuts has led to loss of crops and severe illness in both human and farm 
stock where contaminated food is ingested. For example, Fusarium graminearum, an 
important plant pathogen, is the major reason of fusarium head blight in wheat. This 
is one of the most serious wheat diseases in Midwest and central Canada. Its 
metabolite vomitoxin (also known as deoxynivalenol, DON) of F. graminearum 
belongs to a class of mycotoxins, tricothecenes, which are strong protein inhibitors. 
Contaminations of grains cause loss of billions of dollars every year. 
Current therapeutic approaches for fungal infections rely mainly on antifungal drugs 
that target ergosterol of cell membranes and glucans of cell walls. However, the 
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over-reliance on limited targets has led to a rapid increase in drug resistance. Thus, it 
is important to continue the discovery and development of new antibiotics. 
 
 
 
 
 
 
 
 
Figure 2-1. Classification of antifungal drug and typical examples. 
 
Natural products are the most prolific source of anti-infectives and anticancer agents. 
About 70-80% of anti-infectives and anticancer drugs can be traced to or were 
inspired by natural products. Traditionally, soil bacteria, especially Streptomyces, 
have been the primary source for anti-infectives. More recently, marine organisms are 
also emerging as new sources for bioactive natural products with new structures and 
activities. However, the success has been limited partly due to difficulties with access 
to the marine organisms. In contrast, many “user-friendly”, prolific natural product 
producers from terrestrial environments, other than the Gram-positive Streptomyces, 
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remain largely unexplored, such as the Gram-negative environmental bacteria 
Lysobacter26, 78.  
A number of Lysobacter species are now recognized as microbial predators with an 
impressive arsenal of bioactive small molecules, which gives them potential both as 
biocontrol agents and producers of promising drug leads. 
 
 
 
Figure 2-2. Lysobacter enzymogenes strain C3 and its antifungal activity. (These 
photos were taken by Prof. Gary Yuen at Department of Plant Pathology, UNL)  
 
Our lab has been using Lysobacter enzymogenes strain C3 as a new source for 
bioactive natural products discovery. Lysobacter enzymogenes strain C3 (previously 
named Stenotrophomonas maltophilia strain C3) was originally isolated from grass 
leaves77.
 
This strain is used as a biocontrol agent against fungal pathogens of plants. 
C3 exhibits wide antifungal activity; it can inhibit the growth of many fungi, such as 
Bipolaris sorokiniana and Fusarium graminearum. Our previous screening for 
antifungal compounds from L. enzymogenes strain C3 has led to the isolation of 
heat-stable antifungal factor (HSAF)26, 78, 91, 92. 
HSAF belongs to the polycyclic tetramate macrolactam (PTM), which is emerging as 
a new family of natural products with a distinct structure and new mode of action. 
HSAF contains a 5,5,6-tricyclic system fused with a 17-membered macrolactam that 
33	  	  
	  
includes a tetramate acid moiety. Tetramic acid is the key structural feature for many 
bioactive heterocycles that exhibit a wide range of biological activities including 
antibiotic and anticancer activities. 
 
 
 
 
 
 
 
Figure 2-3. Chemical structure of PTMs.  
 
The results of mode of action test indicated that HSAF specifically interferes with the 
biosynthesis of sphingolipids78. Sphingolipids represent an attractive new target for 
the development of novel antifungal drugs because their structure in fungal cells is 
distinct from that in mammalian cells. This novel mode of action together with the 
unusual chemical structure that is distinct from any existing antifungal drug on the 
market, make HSAF a potentially promising drug lead. 
Through our previous study76, the genetic locus responsible for HSAF biosynthesis in 
L.e. C3 and L.e. OH11 was identified. A series of disruption experiments defined 10 
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HSAF core genes, including a hybrid PKS-NRPS, making up a total of nine domains, 
and 6 flanking redox genes.  
 
 
 
 
 
 
 
 
 
 
Figure 2-4. The dihydromaltophilin (HSAF) biosynthetic gene cluster. The “HSAF 
core” is highlighted in red for PKS-NRPS and blue for the redox enzymes76. 
 
We previously expressed and purified the NRPS protein76. The in vitro 
characterization demonstrated that the NRPS is responsible for forming the two amide 
bonds as well as the carbon-carbon bond between ornithine’s carbonyl carbon and one 
hexaketide’s α carbon, forming the expected tetramate product (Figure 2-5)76. The SD 
enzyme was able to convert a 3-deOH HSAF to HSAF in the presence of NADPH in 
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vitro93. The result demonstrated that the SD gene is the 3-hydorxylase whose activity 
could be significantly enhanced when co-expressed with the ferredoxin reductase 
gene (Figure 2-6). 
 
 
 
 
 
Figure 2-5. In vitro synthesis of a tetramate product using the purified 
dihydromaltophilin NRPS. The acyl-S-ACP substrate was prepared by incubating 
ACP and stearoyl-CoA with Svp, and Orn-S-NRPS was prepared by incubating NRPS 
and CoA with Svp, followed by addition of L-ornithine and ATP.  
 
 
 
Figure 2-6. Hydroxylation of the carbon-3 of 3-deOH HSAF by Sterol Desaturase. 
 
The most striking feature of the cluster is that only a single module PKS-NRPS is 
present, although the biosynthesis of HSAF apparently required two separate 
hexaketide chains that are linked together by one amino acid ornithine via two amide 
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bonds. This suggests that the same PKS module would act not only iteratively, but 
also separately. However, prior to our work, typical bacterial modular PKSs were 
known to be non-iterative, and there had been no report of a bacterial iterative PKS 
that was capable of making two separate polyketide chains. 
Clearly, there is a novelty in the molecular logic of HSAF biosynthesis in which 
nature employs known “old” enzymes to form distinct “new” structures. The goal 
here is to prove that the single-module PKS-NRPS is sufficient for two separate 
polyketide chains and the tetramate macrolactam, which is fused to a 5,5,6-tricyclic 
system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7. Hypothesis for formation of the key intermediate: polyene tetramate 
formation26. 
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2-2 Materials and Methods   
2-2-1. Strains, Vectors, Chemicals, and Molecular Biology Agents  
Escherichia coli DH5α and EPI300 (Epicenter Biotechnologies, Madison, WI) were 
used as the hosts for general plasmid DNA propagation. E. coli SG13009 (pREP4) 
were used for protein expression. E. coli BW25113/pKD46 was used for Red 
recombination. E. coli ET12567/pUZ8002 was used as the conjugal strain. 
Streptomyces sp. LZ35 was isolated from the intertidal soil collected at Jimei, Xiamen, 
China94. Strain SR107 was derived from Streptomyces sp. LZ35 by deletion of four 
PKS gene clusters95. Strain ZM12 was derived from S. coelicolor by deletion of all 
ten native PKS and NRPS gene clusters present in its genome96. Strains SR107 and 
ZM12 were used as the hosts for the heterologous production of HSAF. Vector 
pANT841 was used for general cloning, vector pQE60 was used for protein 
expression in E. coli SG13009 (pREP4), and vector pSET152 was used for integration 
of the HSAF gene cluster into Streptomyces hosts. Chemicals were purchased from 
Sigma or Fisher Scientific. PCR primers were synthesized by Integrated DNA 
Technologies (IDT, Coralville, IA). Kits for plasmid preparation and DNA extraction 
were from Qiagen (Valencia, CA). Standard molecular biology methods were used for 
all other DNA manipulations.  
2-2-2. HSAF polyketide synthase (PKS) expression in E. coli 
The procedure for constructing the entire PKS gene (5526 bp) for expression in E. 
coli is illustrated in Figure 2-8. Two of the three pieces that make up the complete 
PKS gene were amplified by PCR using Cos4'-1 as the template. The following two 
pairs of primers were used for the PCR: 
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P1, KS-NcoI-Forward: 5'-GAG ACC ATG GAG GAC CGC ATC GCC A-3'  
P2, KS-EcoRI-Reverse: 5'- CAT CAT CGT GCC GGT GGC GGT G-3' 
P3, ACP-KpnI-Forward: 5'- ACC GCG GCG ATG CGG TCG AAC-3' 
P4, ACP-BamHI-Reverse: 5'- GGG AAG GAT CCC AGC GCG TTC TGG T-3' 
 
Amplification of the entire PKS gene (5526bp) failed after multiple trials. The 
construction of PKS expression vector is shown in Figure 1-12.  
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Figure 2-8. The construction of PKS expression vector. 
 
The KS-fragment (218 bp) was digested with NcoI and EcoRI; the ACP-fragment 
(1411 bp) was digested with KpnI and BamHI. Both of the fragments were cloned into 
pANT841 at the same sites. The middle fragment was obtained by digestion of 
cosmid COS4-1 with EcoRI, followed by digestion of the resulting selected fragment 
(5941 bp) with KpnI. The final targeted fragment (3897 bp) was cloned into 
pANT841 at the same sites. The construct was sequenced, and the result showed that 
the three fragments were ligated together and the entire PKS gene sequence was 
correct. The PKS gene was released from pANT841 as a BamHI/NcoI fragment and 
cloned into expression vector pQE60.  
2-2-3. Expression and purification of PKS protein. 
To express the PKS, the pQE60 construct was introduced into E.coli SG13009. Single 
colonies were inoculated in 3 ml of liquid LB medium containing ampicillin (50µg/ml) 
and incubated in a shaker (250 rpm) at 37°C overnight. The overnight culture was 
added to 50 ml fresh LB medium and incubated in a shaker (250 rpm) at 37°C until 
the cell density (OD600) reached 0.6. To induce the expression of the PKS, IPTG 
(0.3mM) was added to the culture, and the cells were allowed to grow at the room 
temperature for another 12 hours. To prepare the soluble fraction, the cells were 
harvested and resuspended in 2 ml of PBS buffer (500 mM NaCl, 50 mM Na2HPO4, 
50 mM NaH2PO4, pH 7.8). The cell suspension was sonicated on ice. The soluble 
fraction of protein extracts was loaded onto a Ni-NTA column which was previously 
calibrated with PBS buffer containing 10 mM imidazole. The column was washed 
three times with the buffer containing 20 mM imidazole, and the C-His6-tagged PKS 
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protein (199.8 kDa) was purified by using an imidazole step-gradient as described by 
the manufacturer’s protocol. The purity of the protein was analyzed by SDS-PAGE, 
and the fractions containing purified protein were pooled, concentrated, and dialyzed 
against 50 mM NaCl, 50 mM Na2HPO4, 50 mM NaH2PO4, pH 7.8, containing 15% 
glycerol. Finally the protein solution was frozen in liquid nitrogen and stored at 
-80 °C until use.  
2-2-4. In vitro assay for the activity of the PKS module 
 
 
 
 
 
Figure 2-9. Reactions of PKS activation and polyketide chain assembly.  
 
The first step was to convert the purified PKS to its holo form, through 
4'-phospho-pantetheinylation at the active site serine residue of its ACP domain. This 
was carried by Svp97, a promiscuous 4'- phosphopantetheinyl transferase (PPTase). 
The reaction contained the PKS protein (25 µM), CoA (2 mM) and Svp (10 µM), in a 
45 µl solution of Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and TCEP (0.5 mM). 
After incubation at 37 °C for 2 h, the reaction was stopped by boiling for 10 min. Due 
to the huge size (199.8 kDa) of the PKS protein, a trypsin digestion procedure was 
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employed prior to the ESI-Q-TOF analysis of the mass of the PKS. The protein was 
loaded to a SDS-PAGE (7.5%), and the PKS band was excised from the gel and 
subjected to trypsin digestion98. Briefly, gel pieces were digested by trypsin 
(no.V5111, Promega, Madison, WI) and digested peptides were extracted in 5% 
formic acid / 50% acetonitrile and separated using C18 reversed phase LC column (75 
micron × 15 cm, BEH 130 , 1.7 micron Waters, Milford, MA). A Q-TOF Ultima 
tandem mass spectrometer couple with a Nanoaquity HPLC system (Waters) with 
electrospray ionization was used to analyze the eluting peptides. The system was user 
controlled employing MassLynx software (v 4.1, Waters) in data-dependent 
acquisition mode with the following parameters: 0.9-sec survey scan (380–1900 Da) 
followed by up to three 1.4-sec MS/MS acquisitions (60–1900 Da). The instrument 
was operated at a mass resolution of 8000. The instrument was calibrated using the 
fragment ion masses of doubly protonated Glu-fibrinopeptide. The peak lists of 
MS/MS data were generated using Distiller (Matrix Science, London, UK) using 
charge state recognition and de-isotoping with the other default parameters for Q-TOF 
data. Data base searches of the acquired MS/MS spectra were performed using 
Mascot (Matrix Science, v2.2.0, London, UK). The NCBI database (20100701) was 
used in the searches. Search parameters used were: no restrictions on protein 
molecular weight or pI, enzymatic specificity was set to trypsin with up to 3 missed 
cleavage sites, carbamidomethylation of C was selected as a fixed modification, and 
methionine oxidation was selected as a variable modification. Mass accuracy settings 
were 0.15 dalton for peptide mass and 0.12 dalton for fragment ion masses. The 
apo-PKS, holo-PKS, and the various forms of acylated PKS were analyzed by the MS 
method, which had been successfully used in other studies99, 100. 
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To test the activity of the PKS, the reaction mixture (45 µl) containing the holo-PKS 
was added with malonyl-CoA (10 mM), NADPH (10 mM) and acetyl-CoA (2 mM), 
and the final volume was brought to 50 µl. The reactions were incubated at 37 °C for 
20 h. A reaction containing boiled PKS protein served as the control. The reactions 
were stopped by boiling for 10 min, and a 10 µl aliquot of the reaction mixtures was 
loaded on SDS-PAGE (7.5%), and the PKS band was cut out for trypsin digestion. 
Since the acyl chain synthesized by the PKS could have various chain lengths and 
oxidation levels, the samples were subject thorough search for various potential 
acylated products. 
2-2-5. Expression of PKS with a point-mutated KS domain in E. coli and activity 
assay of the synthase 
The in vitro data obtained from the purified PKS suggest that the synthase may use 
malonyl-CoA as both the starter and the extender in the polyketide chain synthesis 
because a carboxylate appeared present in the intermediate (Figure 2-18). To probe 
the starter specificity, we generated another PKS expression construct, in which the 
active site cysteine in the KS domain of this PKS was mutated to alanine (C176A, 
with the protein accession number ABL86391). Primer extension PCR was performed 
to generate a 2151-bp fragment of PKS gene with C176A mutation. The following 
two pairs of primers were used to amplify a 359-bp fragment and a 1832-bp fragment 
(Figure 2-19): 
KS (C/A) up-fw: 5'-CGC GGC GGC TAC ATC GAC GGC TTC GAC G-3' 
KS (C/A) up-rv: 5'-GGC GAC CAG GGA GGA ACT AGC GGC GGT GTC GAT 
CGA CAG GCT-3' 
KS (C/A) down-fw: 5'-AGC CTG TCG ATC GAC ACC GCC GCT AGT TCC TCC 
CTG GTC GCC-3' 
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KS (C/A) down-rv: 5'-GTA GAG CTC GTG GCC GGC GGC GAT GCC-3' 
 
 
 
 
 
 
 
Figure 2-10. Mechanism of determination of the starter unit by active-site 
point-mutation in the KS domain. 
 
After purification of the PCR fragments, an overlapping PCR was carried out using 
these 2 fragments as template. The resulted 2151-bp fragment was digested with 
EcoRI and SacI, and cloned into previously constructed pANT841-PKS (Figure 2-12) 
at the same sites. The mutated PKS gene (mPKS) was released from pANT841 as a 
BamHI/NcoI fragment and cloned into expression vector pQE60 (Figure 2-19). The 
subsequent expression and purification are the same as for the wild type PKS. 
To assay the activity, mPKS (25 µM) was first converted into its holo form, by 
incubating with CoA (2 mM) and Svp (10 µM) in a 50 µl reaction containing 
Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and TCEP (0.5 mM). After incubation 
at 37 °C for 2 h, the reaction mixture was added with 10 mM malonyl- CoA, 2 mM 
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acetyl-CoA, and 10 mM NADPH. A reaction containing the wild type PKS served as 
the control. After continual incubation at 37°C for 20 h, the reactions were stopped by 
boiling. A 10 µl aliquot of the reaction mixtures was loaded on SDS-PAGE for 
analysis. The mPKS band was cut from the gel and subject to trypsin digestion and 
Q-TOF MS analysis as described above. 
2-2-6. In vitro reconstitution of the PKS module and the NRPS module 
The PKS module was activated to its holo-form and incubated with proper substrates 
as described in the reactions above. The expression and purification of the NRPS 
module had been described previously76. The purified NRPS module was also 
converted to its holo form by incubating with CoA (0.83 mM) with Svp (5.6 µM) in a 
60 µl reaction containing Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and TCEP 
(0.5 mM). The reactions were incubated at 37 °C for 2 h. The NRPS reaction mixture 
and the PKS reaction mixture were then combined into a tube, which had a 40 µl 
solution containing L-Orn (1.5 mM), ATP (3 mM), Tris-HCl (100 mM, pH 8.0), 
MgCl2 (10 mM), NaCl (50 mM), EDTA (0.1 mM), and TCEP (0.5 mM). For control, 
the reaction contained all the components of the reconstitution reaction except that 
NRPS was replaced with the total proteins of the E. coli host strain that was 
transformed only with the blank expression vector pQE60. After continual incubation 
for 5 h at 37 °C, the reactions were stopped by adding 150 µl of 0.2 mM TCA in 
methanol and were frozen at -20 °C for 30 min. The mixtures were centrifuged at 
13,200 rpm for 20 min in a desktop Eppendorf centrifuge, and the supernatants were 
transferred to new tubes. The solutions were dried in a Speed-Vac, and the residues in 
the tubes were re-dissolved in 150 µl methanol. The methanol extracts were 
centrifuged, and supernatants were transferred to new tubes and dried again. Finally, 
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the residues in the tubes were re-dissolved in 300 µl 50% methanol and analyzed by 
LC-MS. The sample (50 µl) was loaded to a Waters BEH column (C18 1.7 µm, 1.0 × 
100 mm), and eluted with the following solvent program: Solvent A was H2O 
containing 0.1% formic acid; Solvent B was acetonitrile containing 0.1% formic acid. 
The flow rate was 50 µl/min with a binary gradient system (0-15 min, 5%-45% B 
gradient; 15-35 min, 45% B to 90% B gradient; 35-46 min, 90% B to 100% B 
gradient; 46-55 min, 100% B; 55-56 min, 100% B to 5% B gradient; 56-66 min, 5% 
B). The mass spectrometer was Mass Spec Waters Snapt G2-S Q-TOF, operated in 
positive ion high resolution mode with lock mass, mass range 100-1200 amu, 1sec 
scans. The LC-MS was set to scan for various masses of potential products that could 
be synthesized by the reconstituted PKS-NRPS and then released into the medium by 
the thioesterase (TE) domain in the NRPS module76, 79, 92, 101. One eminent peak at 
15.48 min was detected in the reconstituted reaction, but no in the control reaction, 
when the scan was at m/z 475.2597 (Figure 2-23). This peak was subject to 
HR-ESI-MS analysis and gave m/z 475.2572 (Figure 2-23). This mass is coincident 
with the expected [M+H]+ for the polyene tetramate intermediate. 
2-2-7. Construction of HSAF expression vectors and heterologous production in 
Streptomyces 
To subclone the HSAF gene cluster into the integrative vector pSET152, two 
restriction sites, AclI and BamHI, were introduced into the vector by insertion of two 
DNA fragments (Figure 2-11). The two fragments (1.4 and 1.7 kb) were amplified 
from the cosmid clone, Cos4'-1, which contains the entire HSAF gene cluster isolated 
from Lysobacter enzymogenes C378. The following two pairs of primers were used for 
the PCR: 
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HSAF-LF: 5'-GAA GAT CTC GGG AAA CTC CGA GGC AGA AAT-3'  
HSAF-LR: 5'-AGG AAT TCC GGT GAT GCA AGG GCT GTC GA-3'  
HSAF-RF: 5'-AGG AAT TCA ACA CCT GGA GTT CTT CAG CAT CA-3'  
HSAF-RR: 5'-GAA GAT CTA AAT CAG CGC CGG TGG CGT TG-3' 
 
 
 
 
 
 
 
 
Figure 2-11. Strategy for constructing the HSAF expression vectors for the 
production of HSAF analogs in Streptomyces hosts. A, construct pSETHSAF3 that 
resulted in the recombinant Streptomyces strains SR107HSAF1 and ZM12HSAF1; B, 
construct pSETHSAF4 that resulted in the recombinant Streptomyces strain 
SR107HSAF2; C, construct pSETHSAF5 resulting in the recombinant Streptomyces 
strain SR107PKS/NRPS. 
 
The resulting PCR products were digested with BglII and EcoRI, respectively, and 
ligated to the BamHI- digested pSET152 to create pSETHSAF1. Then, a 17.2 kb 
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fragment harboring the bulk of the HSAF gene cluster was cut off from Cos4'-1 by 
digestion with AclI and BamHI and inserted into the same sites of pSETHSAF1 to 
yield pSETHSAF2 (Figure 2-11). 
The λ Red mediated recombination in E. coli BW25113/pKD46102 was used to 
replace the native promoter of the PKS-NRPS gene or of the SD gene with 
Streptomyces ermE* promoter103, 104. About 100 ng of pSETHSAF2 was transformed 
into E. coli BW25113/pKD46 by electroporation at 2500 V, 25 µF, and 200 Ohms. 
Clones were selected on solid LB agar with 100 µg/ml ampicillin and 30 µg/ml 
apramycin. The transformants were cultured in LB medium at 30 °C and induced by 
addition of 10 mM L-arabinose for the expression of the red genes. Two fragments 
including the chloramphenicol-resistance cassette (Cm) and the ermE* promoter were 
amplified from pUC19-Cm-PermER* (unpublished data) using the following two 
pairs of primers, respectively: 
ER2HSAFF: 5'-gaa cca gtt tgt tcc aga tca cgg ccg gaa cgc gtt ccg ACA GCT TAT 
CAT CGA ATT TC-3'  
ER2HSAFR: 5'-gcg gca gcc gat gcc gat gat ggc gat gcg gtc ctc cat ATG TCC GCC 
TCC TTT GGT CG-3'  
CmER2SDF: 5'-cgc cgc ggc cta gcc gcg aat att cgc cgg cat tat ctg ACA GCT TAT 
CAT CGA ATT TC-3'  
CmER2SDR: 5'-agc acg cgt ttc caa agt gtg ctc tga taa tcc gtt cat ATG TCC GCC TCC 
TTT GGT CG-3' 
(note: the bases in lower case are the sequence for Red recombination, and the bases 
in upper case are for amplification of the target genes) Each of the fragments (~ 200 
ng) was electroporated into E. coli BW25113/pKD46/pSETHSAF2 to generate 
pSETHSAF3 and pSETHSAF4, respectively. Transformants were selected for 
resistance to chloramphenicol at 25 µg/ml. In addition, the 10 kb SpeI /NheI fragment 
from pSETHSAF3 was inserted into the XbaI site of pSET152 to create pSETHSAF5, 
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which only contained the PKS/NRPS gene with the ermE* promoter. The constructs 
pSETHSAF3-5 were individually transformed into E. coli ET12567/pUZ8002, which 
were used to mate with Streptomyces sp. SR107 and ZM12. This intergenetic 
conjugation resulted in the transfer of three different HSAF expression constructs into 
Streptomyces hosts, construct pSETHSAF3 leading to the recombinant strains 
SR107HSAF1 and ZM12HSAF1, construct pSETHSAF4 to strain SR107HSAF2, and 
construct pSETHSAF5 to strain SR107PKS/NRPS. 
2-2-8. Production and analysis of the metabolites in Streptomyces strains 
For production of secondary metabolites, all Streptomyces strains were inoculated on 
petri dishes containing the Fermentation Medium (soluble starch 25 g, soybean 15 g, 
yeast extract 2 g, agar 20 g, pH 7.2, 40 ml) and cultivated at 28 °C for 11 days. The 
whole solid cultures were diced and extracted with AcOEt/MeOH/AcOH (80:15:5, 
v/v/v) at room temperature, and the crude solution was concentrated under reduced 
pressure. The dried extract was dissolved in 2 ml methanol, and a 20 µl aliquot of 
each extracts was analyzed by HPLC (Agilent 1200, ZORBAX Eclipse XDB-C18, 
4.6×250 mm, 5 µ). For SR107HSAF1-2 and ZM12HSAF1, chromatographic 
conditions were as follows: solvents-A, water-0.04% trifluoroacetic acid (TFA); 
solvent-B, acetonitrile-0.04% TFA; solvent gradient from 20% B to 35% B in the first 
3 min, increased to 45% at 10 min, to 90% B at 17 min, followed by 3 min with 90% 
B, to 100% B at 22 min, followed by 4 min with 100% B; flow rate 1 ml/min and UV 
detection at 380 nm or 318 nm (Figure 2-24). For SR107PKS/NRPS, 
chromatographic conditions were as follows: solvents-A, water-0.1% formic acid 
(FA); solvent-B, acetonitrile-0.1% FA; solvent gradient from 20% B to 55% B in the 
first 5 min, increased to 70% at 8 min, followed by 8 min with 70% B, to 100% B at 
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17 min, followed by 3 min with 100% B, to 20% B at 21 min, followed by 4 min with 
20% B; flow rate 1 ml/min and UV detection at 380 nm (Figure 2-26). 
2-2-9. Isolation and structure determination of compounds 2 and 3 
SR107HSAF culture (10 liters) was allowed to grow on the Fermentation Medium at 
28 °C for 11 days. The whole solid cultures were diced and extracted three times with 
AcOEt/MeOH/AcOH (80 : 15 : 5, v/v/v) at room temperature, and the crude extract 
solution was concentrated under reduced pressure, and the concentrated extract was 
sequentially solvent partitioned into petroleum ether-soluble extract and 
MeOH-soluble extract. The MeOH extract was loaded to a Sephadex LH-20 column 
for separation. The column was eluted with MeOH to obtain six fractions, Fr.1 - 6. 
Fr.3 was subjected to medium-pressure liquid chromatography (MPLC; 80 g RP-18 
silica gel; acetonitrile/H2O 30%, 50%, 70%, 80%, and 100%, 200 ml each) to afford 
five subfractions, Fr.3a – 3e. Fr.3c (60 mg) was subjected to preparative HPLC 
(Agilent 1200, ZORBAX Eclipse XDB-C18, 9.4×250 mm, 5 µ), using an isocratic 
solvent of 55% acetonitrile-0.04% TFA, at flow rate of 4 ml/min, detected at UV 360 
nm. This afforded compound 2 (10 mg) and compound 3 (4 mg). To determine the 
structures of the compounds, 1D- and 2D-NMR were performed on a Bruker 
DRX-600 spectrometer. MS was carried out on an LTQ-Orbitrap-XL mass 
spectrometer (Thermo Scientific). 
2-2-10. LC-MS-MS analysis of the metabolites in strain SR107PKS/NRPS 
Strain SR107PKS/NRPS containing the construct pSETHSAF5 (PKS-NRPS alone 
under the control of ermE* promoter) generated three new peaks as shown in Figure 
2-24. To identify the metabolites, the peaks were individually collected from HPLC, 
and each of the peaks was further analyzed by UV-Vis spectrometry and 
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HPLC-HRMS using a Prominence Modular HPLC (Shimadzu Corporation, 
YMC-Pack Pro C18, 5 µm, 4.6 × 250 mm) coupled to a LTQ Velos Pro HRMS 
instrument (Thermo Scientific). For peak1, chromatographic condition was 60% 
acetonitrile/H2O (containing 0.2% FA) for 10 min; for peaks 2 and 3, 
chromatographic condition was 85% acetonitrile/H2O (containing 0.2% FA) for 10 
min. 
 
2-3 Result and discussion 
The HSAF biosynthetic gene cluster contains only a single-module polyketide 
synthase-nonribosomal peptide synthetase (PKS-NRPS), although the PTM scaffold 
is apparently derived from two separate hexaketide chains and an ornithine residue. 
This suggests that the same PKS module would act not only iteratively, but also 
separately, in order to link the two hexaketide chains with the NRPS-activated 
ornithine to form the characteristic PTM scaffold. In the following sections, I describe 
the results on formation of tetramate polyenes in vitro using the individually purified 
PKS and NRPS, and on production of the Gram-negative Lysobacter-originated 
HSAF in Gram-positive Streptomyces heterologous hosts. The results provide direct 
evidence for this highly unusual biosynthetic mechanism that is likely general for the 
PTM- type hybrid polyketide-peptides. 
2-3-1. HSAF polyketide synthase (PKS) expression in E. coli 
To obtain direct evidence for this iterative single-module PKS, we expressed the PKS 
in E. coli and purified the 199.8 kDa protein (Figure 2-13). To test its activity, we 
converted the PKS to its holo form by incubating it with CoA and Svp, a promiscuous 
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4'-phosphopantetheinyl transferase (PPTase)105. Due to the huge size of this protein, 
we treated the PKS with trypsin after the reaction and followed the mass change of 
the tryptic fragment within the ACP domain of the PKS, to which the PPT moiety and 
biosynthetic intermediates are covalently linked. Specifically, the trypsin digestion is 
predicted to release a 26-residue fragment, VKPEQIDADASLNALGLDSLLAMELR 
(the active site serine residue underlined), within the ACP domain. 
 
 
 
 
     (A)                    (B)                           (C) 
Figure 2-12. Construction of expression vector pQE60-PKS. A: PCR results of 
KS-fragment and ACP-fragment. B: Middle fragment digested from Cosmid4-1by 
EcoRI/KpnI (after digestion of Cosmid4-1 by EcoRI, the 5941bp band was purified 
and digested by KpnI into 2 fragments (3897bp and 2044bp)). C: Double digestion 
check of pQE60-PKS construction by NcoI/BamHI. 
 
 
 
 
 
52	  	  
	  
Figure 2-13. SDS-PAGE of the HSAF PKS expressed in E. coli. M, markers; BI, 
total proteins before IPTG induction; SN, total soluble proteins after sonication; P, 
total precipitated proteins after sonication; FT, flow-through fraction of the Ni-NTA 
column; WB1-3, wash-off fractions of the Ni-NTA column; EB1-15, imidazole-eluted 
fractions of the Ni-NTA column. The purified PKS is indicated with an arrow. 
 
2-3-2. In vitro assay for the activity of the PKS module 
The trypsin digestion of this apo-PKS is expected to release a 26-residue fragment, 
VKPEQIDADASLNALGLDSLLAMELR, which contains the active site serine 
residue (underlined) of the ACP domain of the PKS (Table 2-1, shown the mass of a 
number of selected ions, both the predicted and the observed). Q-TOF MS data 
showed that the tryptic fragment from the apo-PKS isolated from E. coli had m/z 
928.1374 for [M+3H]3+ (calculated 928.1604) (Figure 2-15). This fragment was 
subject to tandem MS-MS analysis (Figure 2-14). The result showed that this tryptic 
fragment had the expected amino acid sequence, confirming that the 199.8 kDa 
protein purified from E. coli was HSAF PKS. 
After the correct tryptic PKS fragment was identified, we analyzed the holo-PKS and 
detected a tryptic fragment of m/z 1041.5487 for [M+3H]3+ (calculated 1041.5221) 
and m/z 781.4270 for [M+4H]4+ (calculated 781.3936) (Figure 2-16, Table 2-1). The 
holo-PKS was also confirmed using phosphopantetheine ejection assay106, 107, which 
detected m/z= 357.2021 (calculated 357.0880) for the predicted product 5 (Figure 
2-17). The data showed that the heterologously produced PKS was as expected and 
the enzyme was active. 
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VKPEQIDADASLNALGLDSLLAMELR 
 
 
 
 
 
 
Figure 2-14. Tandem MS-MS data for the tryptic PKS fragment that harbors the 
serine active site of the ACP domain, VKPEQIDADASLNALGLDSLLAMELR. 
 
 
 
 
 
Figure 2-15. Q-TOF MS-MS data for the tryptic PKS fragment that harbors the serine 
active site. (VKPEQIDADASLNALGLDSLLAMELR). 
 
VKPEQIDADASLNALGLDSLLAMELR	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Figure 2-16. Q-TOF MS data for the tryptic fragment of PKS, after 
phosphopantetheinylation by PPTase, Svp, using CoA as substrate. The MS at left 
side showed [M+3H]3+ m/z = 1041.5487 (calculated mass: 1041.52), and the MS at 
right side showed [M+4H]4+ m/z = 781.4270 (calculated mass: 781.39). 
 
Upon 4'-phosphopantetheinylation, the tryptic fragment from the holo-PKS is 
expected to have a 340.1 mass increase. Q-TOF MS data showed m/z 1041.5487 for 
[M+3H]3+ (calculated 1041.5221) (Figure 2-16) and m/z 781.4270 for [M+4H]4+ 
(calculated 781.3936). In addition, the 4'-phosphopantetheinylation of the PKS was 
examined using PPT ejection assay106. The expected compound was detected from the 
holo-PKS (Figure 2-17). The results demonstrated that the apo-form of the PKS 
expressed in E. coli had been converted into its holo-form in vitro. 
Note: during vibrational activation of gas-phase carrier domains, a facile elimination 
occurs in bench-top mass spectrometers. The phosphopantetheine ejection pathways 
have been observed. The actual MS spectrum is shown below. 
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Figure 2-17. MS detection of the compound resulted from a PPT ejection, with m/z 
357.2021 for [M]- (calculated 357.0891). 
 
Next, we sought for potential biosynthetic intermediates that were covalently attached 
to the ACP domain of the PKS. Upon incubating the holo-PKS with acyl-CoA and 
NADPH, the tryptic fragment released from the PKS showed m/z 1113.4847 for 
[M+3H]3+ (calculated 1113.5533) and m/z 835.4001 for [M+4H]4+ (calculated 
835.4170) (Figure 2-18). This mass change of the ACP fragment is coincident with a 
hexaketide polyene intermediate attached to the PPT of the PKS (Figure 2-18). We 
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also varied reaction conditions and searched for other potential biosynthetic 
intermediates with a varied carbon chain.  
 
 
 
 
 
Figure 2-18. Polyene production in the in vitro reaction of PKS. The PKS protein was 
digested by trypsin, and the tryptic fragments were analyzed by Q-TOF-MS. The MS 
at left side showed [M+3H]3+ m/z = 1113.4847 (calculated mass: 1113.55), and the 
MS at right side showed [M+4H]4+ m/z = 835.4001 (calculated mass: 835.40). 
Substrate Predicted 
product 
Predicted Mass (Da) Observed Mass (Da) Error (Da) 
M+3H M+4H M+3H M+4H M+1H 
- apo-PKS 928.1604 696.3722 928.1347 NA 0.0613 
CoA holo-PKS 1041.5221 781.3936 1041.5487 781.4270 0.0798 
Mal-CoA PKS-polyene 1113.5533 835.4170 1113.4847 835.4001 0.2058 
 
Table 2-1. The predicted mass and observed mass of the tryptic PKS fragment 
containing the ACP domain.  
Hexaketide polyene was the only one detected. The results support that the 
single-module PKS found in the HSAF biosynthetic cluster is indeed an iterative PKS, 
preferably to catalyze five cycles of chain elongation in polyketide biosynthesis. 
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Interestingly, the data suggest that the PKS used malonyl-CoA as both the starter and 
the extender in the polyketide chain synthesis because a carboxylate appeared present 
in the intermediate (Figure 2-18). 
2-3-3. Expression of PKS with a point-mutated KS domain in E. coli and activity 
assay of the synthase 
To verify this hypothesis, we generated another PKS expression construct, in which 
the active site cysteine in the KS domain of this PKS was mutated to alanine. Since all 
the domains, except the KS domain, are still active, the synthase is expected to 
transfer the starter unit to the ACP but unable to elongate the polyketide chain. So the 
acyl group from the starter unit will be stuck on the ACP domain. Indeed we detected 
the mass for malonyl-S-ACP, instead of acetyl-S-ACP, and we also detected the mass 
of the mutated KS fragment and the active ACP domain. The result demonstrated that 
PKS prefers malonyl-CoA to acetyl-CoA as the starter. 
 
 
 
 
           (A)                (B)                          (C) 
Figure 2-19. Gel electrophoresis of A: PCR amplification of the KS upstream and 
downstream fragments (359 bp and 1832 bp). These two fragments were used as 
templates in overlapping PCR. The marker is the 1 kb ladder from Fermentas. B: 
Lane 1 is the overlapping PCR fragment (2151 bp), which harbors the C/A mutation 
 1   M  2
1832bp
359bp
M    1    2
6842bp
2151bp
M          1
5562bp
3431bp
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site. Lane 2 is the pANT841-PKS (original) vector digested by EcoRI and SacI. 
Marker is the high range ladder No.393 from Fermentas. C: Lane 1 is NcoI and 
BamHI double digested pQE60-mPKS, resulted in 2 bands that have the same lengths 
(5562 bp and 3431 bp, which are the lengths of mutated PKS and pQE60). 
 
 
 
 
 
Figure 2-20. SDS-PAGE of the mutated PKS expressed in E. coli. M, markers; SN, 
total soluble proteins after sonication; FT, flow-through fraction of the Ni-NTA 
column; EB1-5, imidazole-eluted fractions of the Ni-NTA column. The purified PKS 
is indicated with an arrow. 
 
 
 
 
 
Figure 2-21. Q-TOF MS data for the tryptic fragment of holo-mutated PKS, after 
incubating with acyl-CoA, malonyl-CoA and NADPH. The MS at left side showed 
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[M+3H]3+ m/z = 1069.89 (calculated mass: 1070.19), and the MS at right side 
showed[M+4H]4+ m/z = 802.69 (calculated mass: 802.87). 
 
 
 
 
 
 
            (A)                                     (B) 
Figure 2-22. Q-TOF MS data for the tryptic fragment of PKS, after 
phosphopantetheinylation by the PPTase, Svp, using CoA as substrate. The MS 
showed [M+3H]3+ m/z = 1041.21 (calculated mass: 1041.52). B: Q-TOF MS data for 
the tryptic fragment of PKS (incomplete digestion), which harbored the Cys to Ala 
mutation site. The MS showed [M+3H]3+ m/z = 883.16 (calculated mass: 883.45) 
Starter unit Predicted product 
Predicted Mass (Da) Observed Mass (Da) 
M+3H M+4H M+3H M+4H 
Acetyl-CoA 
 
1055.52 791.86 NA NA 
Malonyl-CoA 
 
1070.19 802.87 1069.89 802.69 
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Table 2-2. The predicted mass and observed mass of the tryptic mutated PKS 
fragment containing the ACP domain. 
 
 
 
 
 
Table 2-3. The predicted mass and observed mass of the tryptic fragment of 
holo-mPKS and the tryptic fragment of PKS, which harbored Cys to Ala mutation. 
 
2-3-4. In vitro reconstitution of the PKS module and the NRPS module 
Finally, we incubated the polyene-S-PKS with L-ornithine-S-NRPS to reconstitute the 
activity of the hybrid PKS-NRPS in vitro. The NRPS module (C-A-PCP-TE, 148.6 
kDa) was separately expressed and purified. Prior to reconstituting the activity, the 
purified NRPS was converted to the holo form by incubating with CoA and Svp, 
followed by incubating with L-ornithine and ATP to form L-ornithine-S-NRPS. Since 
a thioesterase (TE) domain is present in this module, we expect the product(s) be 
released into the reaction medium76, 79, 94. We used LC-MS to search for released 
product(s) of the reconstitution reaction (Figure 2-23). Two closely associated LC 
peaks, one at 21.4 min and one at 23.2 min, were detected when the MS scan was set 
at m/z 475.07-476.07. The peak at 21.4 min gave m/z 475.54, and the peak at 23.2 
Substrate Predicted product 
M+3H 
Predicted Observed 
- Tryptic fragment of holo-PKS 1041.52 1041.21 
- Tryptic fragment with C-A mutation 883.45 883.16 
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min gave m/z 475.60 (Figure 2-23). These peaks were not found in the control 
reaction. The mass of the species in these peaks is in agreement with the production 
of a tetramate-containing polyene-ornithine-polyene product  (calculated 475.26 for 
[M+H]+). Different from the hexaketide polyene produced in the PKS-alone reaction, 
the products from the reconstitution of both PKS and NRPS did not contain the 
carboxylate from the starter malonyl-CoA. Together, the data from the in vitro 
PKS-NRPS reconstitution and from the analysis of the PKS tryptic fragments support 
that the PKS module acts iteratively and, together the NPRS module, are sufficient for 
the synthesis of the framework of PTM. 
 
 
 
 
 
 
Figure 2-23. Analysis of the in vitro reconstituted PKS-NRPS. Total ion 
chromatography of the selected mass (475.2597) for compound 6 is shown for the 
control reaction (top panel) and the PKS-NRPS reaction (bottom). The peak at 15.48 
min in the PKS-NRPS reaction gave m/z 475.2572 in HR-ESI-MS. 
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2-3-5. Construction of HSAF expression vectors and heterologous production in 
Streptomyces 
(I acknowledge Yaoyao Li for construction of HSAF expression vectors and 
heterologous production in Streptomyces.) 
We isolated a cosmid clone, Cos4'-1, from the genomic library of L. enzymogenes C3, 
which contains the entire HSAF biosynthetic gene cluster78. The gene cluster was then 
transferred into vectors for expression in Streptomyces sp. However, the 
transformants failed to produce any detectable HSAF or analogs. Subsequently, we 
made two modifications in the experiments. First, we replaced the putative promoter 
at the 5'-nontranslated region of the PKS-NRPS gene with the ermE* promoter, 
generating pSET152HSAF3 (Figure 2-11). Second, we chose to use an engineered 
host, strain SR107 derived from Streptomyces sp. LZ35 through deleting its four 
native PKS gene clusters. This host is expected to provide a relatively “clean” 
background for the heterologous production of HSAF. We introduced 
pSET152HSAF3 into strain SR107 and analyzed the metabolites in the transformant 
using HPLC. The transformant strain produced approximately seven eminent peaks 
that were absent in the control strain SR107 (Figure 2-24). We first focused our 
attention on the main peak 2 at 18.8 min because it falls in the region that HSAF and 
analogs would appear (16-20 min). 
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Figure 2-24. Chemical structures of HSAF and analogs and production of HSAF 
analogs in Streptomyces. SR107, HPLC analysis of metabolites from Streptomyces sp. 
LZ35 strain SR107, in which four native PKS gene clusters had been deleted; 
SR107HSAF, HPLC analysis of metabolites from strain SR107 containing the HSAF 
biosynthetic gene cluster under the control of ermE* promoter. The first two HPLC 
profiles show the metabolites detected at 380 nm, and the bottom two show the 
metabolites detected at 318 nm. The asterisks indicate peaks that were absent in the 
control. 
Compound 2 was isolated as yellow powder. HR-ESI-MS gave a quasi molecular ion 
at m/z 495.2837 for [M + H]+ (calculated 495.2853 for C29H38N2O5). The complete 
NMR assignments were carried out by the analysis of 1D and 2D NMR data (HSQC, 
HMBC and 1H-1H COSY). The NMR comparison of 2 with alteramide A (4) (Figure 
2-3) indicated that the compounds are structurally similar80, except for the absence of 
the hydroxyl group at C3 and the Z-geometry for C10,C11 double bond in 2 (Figure 
2-24). The relative configuration of 2 was established by proton couplings and NOE 
correlations. The large coupling constants (~ 15.0 Hz) between olefinic protons 
(H8/H9, H21/H22, and H23/H24) led to assignment of the E-configuration for the 
three double bonds, whereas the Z-configuration of C10,C11 double bond was 
deduced from the small coupling constant (11.2 Hz) between H10 and H11. The 
relative stereochemistry of the bicycle unit was determined from the NOESY 
experiment, which is identical to alteramide A (4). 
The rest of the eminent peaks (indicated by asterisks in Figure 2-24) detected at 380 
nm were fairly labile. The compounds eventually disappeared over the process of 
purification. To see if any other isolable HSAF analog was produced in the 
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transformant, we checked the metabolites under other wavelengths. At 318 nm, two 
peaks were detected at the HSAF region, one at 18.8 min (compound 2) and the other 
at 18.6 min (compound 3) (Figure 2-24). These two compounds were not produced by 
the control strain SR107 (at this wavelength, a main peak at 18.6 min was also 
detected in the control, but showed a different UV-Vis spectrum than compound 3). 
Compound 3 was then isolated for structural determination. It appeared as white 
powder, with a quasi molecular ion at m/z 497.3021 for [M + H]+ (calculated 
497.3015 for C29H40N2O5) as determined by HR-ESI-MS. Comparison of the 1H- 
NMR spectrum of 3 to that of 3-deOH-HSAF readily established the structure of 3 as 
3-deOH-HSAF. 
 
 
 
Figure 2-25. UV-Vis spectra of the three peaks observed in HPLC of the metabolites 
from Streptomyces strain SR107PKS/NRPS that was transformed with PKS-NRPS 
alone. A, peak at 11.7 min; B, peak at 16.3 min; C, peak at 20.8 min (polyene 
tetramate intermediate). 
 
The production of compounds 2 and 3 in a Streptomyces strain supports the notion 
that the single-module hybrid PKS-NRPS in pSETHSAF3 is probably sufficient for 
the assembly of the PTM scaffold. To further prove this point, we transferred 
pSETHSAF3 into a second Streptomyces host that has a completely “clean” 
background. Strain ZM12 was derived from S. coelicolor, probably the best-studied 
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model Streptomyces, through deletion of all ten native PKS and NRPS gene clusters 
present in its genome96. HPLC showed that this strain produced very few metabolites. 
However, upon introduction of pSETHSAF3, both compounds 2 and 3 were produced 
as the main metabolites in strain ZM12, in addition to a number of minor peaks. No 
other PKS-NRPS is present in strain ZM12, so our data clearly demonstrated that the 
biosynthesis of HSAF only requires a single-module hybrid PKS-NRPS. The results 
also imply that the five domains (ketosynthase (KS)/acyltransferase (AT)/dehydratase 
(DH)/ketoreductase (KR)/acyl carrier protein (ACP)) of this PKS module act two 
separate times to assemble two separate hexaketide chains. 
Compounds 2 and 3 lack the 3-hydroxy group of HSAF (1), which suggests that the 
sterol desaturase (SD) gene (see Figure 2-4 for the cluster) was not functional in the 
expression construct pSETHSAF3, in which the ermE* promoter was placed in front 
of the PKS-NRPS gene (Figure 2-11). The SD gene encodes the 3-hydroxylase 
converting 3-deOH-HSAF (3) into HSAF93. We subsequently generated a second 
expression construct, pSETHSAF4, in which the ermE* promoter was placed in front 
of the SD gene (Figure 2-11). The construct was introduced into Streptomyces sp. 
SR107 to generate the transformant strain SR107HSAF2. However, a careful search 
of the metabolites in this strain did not find any HSAF-like compound (Figure 2-26). 
The reason for this is unclear at this moment; one possibility is that the insertion of 
the ermE* cassette in front of the SD gene might not lead to transcription of the 
PKS-NRPS gene and downstream tailoring genes because the SD gene and the other 
genes in the cluster do not appear to share the same promoter (Figure 2-11). 
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Figure 2-26. Production of the polyene tetramate 6 in Streptomyces transformed with 
the PKS-NRPS only. HPLC analysis (top); full ESI-MS spectrum of 6 (bottom left) 
and MS/MS analysis of 6 (bottom right). SR107: metabolites from nontransformed 
Streptomyces sp. LZ35 strain SR107; SR107PKS/NRPS: metabolites from the strain 
transformed with only the PKS-NRPS gene under control of the ermE* promoter. The 
metabolites were detected at 380 nm. The asterisks indicate peaks that were absent in 
the control. 
 
Based on the data, we proposed a mechanism for the formation of PTM scaffold 
(Figure 1-6). First, the five-domain PKS module iteratively catalyzes the formation of 
a polyene hexaketide. This hexaketide is transferred to the four-domain NRPS module, 
which activates L-orinithine and catalyzes the first amide bond formation, probably 
between the delta-amino group of L-ornithine and thioester carbonyl group of the 
hexaketide. This leads to a NRPS-bound polyene-ornithine intermediate. Meantime, 
the PKS module continues to assemble the second hexaketide, which is subsequently 
transferred to the NRPS through forming the second amide bond, probably between 
the alpha-amino group of L-ornithine and the second hexaketide chain. The timing of 
this transfer is right after the fifth cycle of polyketide chain elongation, in which the 
newly formed β-keto group of the second hexaketide chain has not been processed by 
the KR domain and DH domain. All PTM natural products contain this keto group in 
the final structure (C-25 in HSAF structure, Figure 2-24).27, 76, 108 The determining 
factor for this timing is not known, but probably related to the redox enzymes that are 
proposed to cooperate with the PKS-NRPS in morphing the PTM scaffold81. The 
transfer of the second hexaketide chain leads to a NRPS-bound 
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polyene-ornithine-polyene intermediate. Finally, the intermediate is released from the 
NRPS by formation of the tetramate unite, which is through the attack of the 
nucleophilic alpha carbon of the second hexaketide at the thioester carbonyl carbon of 
L-ornithine. The presence of the β-keto group on the second hexaketide makes the 
α-carbon a good nucleophile, which promotes the tetramate formation and product 
release. This perhaps contributes to the timing of the transfer of this hexaketide to 
NRPS. In case the β-keto was fully processed, the second polyene chain would not 
undergo tetramate formation, which results in an “unproductive process”. In vivo, the 
tetramate-containing polyketide-ornithine- polyketide is ultimately morphed into the 
PTM scaffold by tailoring enzymes, probably when the intermediate is still 
NRPS-bound. Our previous study showed that this NRPS prefers a C12 chain when 
forming tetramate acyl-ornithine-acyl products in vitro. Thus, the specificity of the 
domain (most likely the C domain) responsible for transferring the polyketide chain 
from the PKS to the NRPS is the key determinant for the macrolactam ring size 
observed in the characteristic PTM framework. 
 
2-4. Summary and final remarks 
HSAF is the main antifungal factor that the biocontrol agent Lysobacter enzymogenes 
uses to fight against fungal diseases and thus to protect crop plants. Lysobacter are 
Gram-negative gliding bacteria; they are ubiquitous in the environment, but largely 
remain untapped for bioactive natural products109. HSAF has a potent activity against 
a broad spectrum of fungi, using a new mode of action. Its chemical structure is 
distinct from any existing fungicide or antifungal drug. Most interestingly, its 
biosynthesis involves an unprecedented mechanism – using a single module 
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PKS-NRPS to assemble two separate hexaketide chains and link them to ornithine 
residue, eventually resulting in a polycyclic tetramate macrolactam. Furthermore, 
PTM-type gene clusters have been identified from numerous bacterial genomes27, 108, 
and yet none of them has been biochemically investigated. 
In over 20 years, bacterial modular PKSs have been found to synthesize polyketides 
using a non-iterative mechanism ⎯ one module catalyzes one cycle of elongation of 
the same polyketide chain. A single-module PKS to catalyze multi-cycle elongations 
of two separate polyketide chains has only been found in the PTM-type PKS. Our 
studies of HSAF provide direct evidence for a previously uncharacterized iterative 
biosynthetic mechanism for bacterial polyketide-peptide natural products. The 
evidence comes from both the in vivo approach - heterologous production of HSAF in 
the Gram-positive bacterial hosts, Streptomyces strains, and the in vitro approach - 
expression of the ~200 kDa PKS and the ~150 kDa NRPS separately in E. coli, 
purification of the giant enzymes, and reconstitution of the biosynthetic activity using 
these two enzymes. In light of the huge number of uninvestigated PTM-type gene 
clusters in databases, our studies present here will facilitate the research of a new area 
of hybrid polyketide-peptide biosynthesis. 
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Chapter 3: Defining the Minimal Gene Cluster Required for PTM Biosynthesis 
Portions of this chapter were reported (Journal of American Chemical Society. 2011, 
144:643-645) and are reproduced with the permission of the publisher76. 
3-1. Background and Significance  
Among the natural products, polycyclic tetramate macrolactam (PTM) are emerging 
as a new class of natural products with a distinct structure and a new mode of action. 
HSAF was discovered from Lysobacter enzymogenes strain C3 that has powerful 
antifungal activity78, 110. HSAF contains a 5,5,6-tricyclic system fused with a 
17-membered macrolactam that includes a tetramate acid moiety. Tetramic acid is the 
key structural feature for many bioactive heterocycles that exhibit a wide range of 
biological activities including antibiotic and anticancer activities. 
 
Figure 3-1. Chemical structure of selected PTMs.  
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Previous study of the mode of action indicated that HSAF specifically interferes with 
the biosynthesis of sphingolipids. Sphingolipids represent an attractive new target for 
the development of novel antifungal drugs because their structure in fungal cells is 
distinct from that in mammalian cells. This novel mode of action together with the 
unusual chemical structure that is distinct from any existing antifungal drug on the 
market, make HSAF a potentially promising drug lead78. 
Through our previous study, the genetic locus responsible for HSAF biosynthesis in 
L.e. C3 was identified76. Since the genes for secondary metabolite biosynthesis often 
cluster together, the complete biosynthetic gene cluster of HSAF may very likely be 
sitting within the region between ORF1 and ORF10, in which there is only one 
PKS-NRPS hybrid (Fig. 3-2). Similar gene clusters were also found by Clardy and 
co-workers from the genomes of a number of Streptomyces strains, all of which 
contain one single modular PKS/NRPS27.  
(A) 
 
 
(B)  
 
 
 
Figure 3-2. (A) Map of HSAF biosynthetic gene cluster. ORFs within the rectangle 
are the putative minimal gene cluster for HSAF biosynthesis. (B) Annotation of the 
genes within the HSAF biosynthetic gene cluster.  
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In the previous work, 3-deOH HSAF was isolated from the disruption mutant of 
Sterol Desaturase (SD) gene within HSAF gene cluster and was observed to be 
transformed into HSAF in the presence of Sterol Desaturase93. This showed that the 
SD gene is also required in modification after the assembly of the HSAF core 
structure. The disruption of the ferredoxin reductase gene led to a lower level of 
dihydromaltophilin and proportional increase of a putative precursor/shunt product, 
suggesting that this gene is related to HSAF production but its role may be 
compensated by other similar genes in the genome. Finally, the disruption of the 
arginase gene (ORF9) had no obvious effect. Arginase catalyzes the conversion of 
arginine to urea and ornithine and is one of the enzymes in the Urea Cycle. This 
arginase may provide ornithine needed in dihydromaltophilin biosynthesis, but it is 
not essential as other arginases in primary metabolism could compensate its function. 
In the meantime, we constructed a series of heterologous expression constructs, as 
illustrated in Chapter 2, and introduced the constructs into S. lividans and analyzing 
the metabolites in the transformants26. The successful isolation of the 
polyene-tetramate-polyene intermediate and 3-deOH HSAF indicated that a single 
PKS-NRPS is sufficient for synthesizing the basic structure of HSAF and that the 
introduction of these core genes into a proper heterologous host will lead to basal 
production of HSAF (or its precursors/analogs).  
As shown in Figure 3-2, this PKS-NRPS is flanked by six redox genes, four 
NADP/FAD-dependent oxidoreductase (OX) genes on the left and a 
hydroxylase/sterol desaturase gene and a NADP/FAD-ferredoxin reductase gene on 
the right. The genes for PKS-NRPS, OX1, 2, 3, and 4 appear to form an operon, 
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because they are either translationally coupled or only have a small intergenic region 
in between. Based on sequence alignment, it is not that all of the 4 redox genes are 
required for biosynthesis of PTMs with different ring systems. For example, in 
ikarugamycin biosynthetic gene cluster, there are only 2 redox genes next to the 
PKS-NRPS hybrid gene, which means that two redox enzymes are enough to make 
the tri-cyclic ring system. If this is applicable for all PTM compounds, it would 
suggest that there is one or two redox genes in HSAF biosynthetic gene cluster is/are 
functionally redundant. A characterization of the exact function of the OXs is 
required.  
The objective of this project was to determine the minimal gene cluster required for 
assembling the hexaketide-ornithine-hexaketide skeleton, forming the tetramic acid 
unit, and synthesizing the 5,5,6-tricylic system of HSAF. My contribution in this 
work is the study of two of the oxidoreductase genes, using mutagenesis approach.   
3-2. Materials and Methods 
All oligonucleotides for PCR reactions were purchased from Integrated DNA 
Technologies (Coralville, IA). Molecular cloning reagents, including DNA 
polymerases, restriction enzymes and T4 DNA ligase, were purchased from New 
England BioLabs (Ipswich, MA).  Chemicals for preparing solid and liquid medium 
were purchased from Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich (St. Louis, 
MO). Chemicals for metabolite extraction and HPLC solvents were purchased from 
Sigma-Aldrich. Plasmid was extracted using Qiagen kits (Valencia, CA). Other DNA 
manipulations were performed according to the procedure described in molecular 
cloning manuals. Plasmid DNA was propagated in Escherichia coli strain XLBLUE1.  
Escherichia coli strain S17-1 served as the host for the conjugal transfer of 
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replacement cassettes cloned in conjugation vector pJQ200SK. All PCR targeting 
gene transfers were performed using Escherichia coli strain BW25113. 
3-2-1. Generation of four OX gene disruption mutants 
(note: I acknowledge Yaoyao Li for preparing the four oxidoreductase gene disruption 
mutants.)  
To construct the gene disruption vectors, an internal fragment was amplified from 
each of the four OX genes using the primer pairs listed below. 
OX1For 5’-GCC GCT GGA GAA CTG GAA GG-3’ 
OX1Rev 5’-GCTGAA GTA GGT GAC GTG GAT GA-3’ 
OX2For 5’-GCT GTA CCC GTT CCT GAC GC-3’ 
OX2Rev 5’-TTC TTC CTC GCT GAG CAG ATA AGT-3’ 
OX3For 5’-TCC CGG TGC TGC CGT TCT A-3’ 
OX3Rev 5’-TGC GGT TCG GCG ATG GT-3’ 
OX4For 5’-AAG CTC GAC CTG CGC CAC T-3’ 
OX4Rev 5’-TTC TGC TCG GTG AAC CAC TCC-3’ 
The sizes of the PCR fragments for OX1, 2, 3, and 4 were 712, 622, 328 and 539 bp, 
respectively. The fragments were cloned into pGEM-T vector and their identity was 
confirmed by DNA sequencing. Each of the fragments was then transferred to the 
conjugal vector pJQ200SK as an ApaI/SpeI fragment to produce pJQ200SK-OX1-4. 
Each of the pJQ200SK-OX was transformed into E. coli S17-1, which was mated 
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with Lysobacter enzymogenes C3 for conjugal transfer of the constructs. The positive 
colonies grown on LB plates containing gentamicin (20µg/ml) and kanamycin 
(25µg/ml) were picked up and inoculated into liquid cultures containing these two 
antibiotics with same concentration. 
Genomic DNA was prepared from each of the cultures, and diagnostic PCR reactions 
were performed to identify mutants that resulted from a homologous recombination at 
the respective OX genes. The following primer pairs were used for these experiments. 
MOX1For 5’-GGG CAA CAA CGC CAA CC-3’ 
MOX1Rev 5’-CCC TCA TCA GTG CCA ACA TAG-3’ 
MOX2For 5’-CTG CAT CGA ATG GCT GAT C-3’ 
MOX2Rev 5’-TCT TTA TAG TCC TGT CGG GTT T-3’ 
MOX3For 5’-CCC CTA CTT CAA CGC CAT CC-3’ 
MOX3Rev 5’-CAC CCT CAT CAG TGC CAA C-3’ 
MOX4For 5’-ACC TTC CCG ATG GTG TTCC C-3’ 
MOX4Rev 5’-ACG ACC GAG CGT AGC GAG T-3’ 
In each of the primer pairs, the forward primer will anneal to the corresponding OX 
gene at a location that is outside the PCR fragment used in the gene disruption 
constructs, and the reverse primer will anneal to a location within pJQ200SK vector. 
The expected size of the PCR product from OX1 mutants was 1345 bp, which will 
release two fragments of 1000 and 345 bp upon ApaI digestion. The expected size of 
the PCR product from OX2 mutants was 1566 bp, which will release two fragments 
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of 916 and 650 bp upon ApaI digestion. The expected size of the PCR product from 
OX3 mutants was 839 bp, which will release two fragments of 492 and 347 bp upon 
ApaI digestion. The expected size of the PCR product from OX4 mutants was 1072 
bp, which will release two fragments of 611 and 461 bp upon ApaI digestion. As 
shown in Figure 3-3, the diagnostic PCR and ApaI digestion produced the expected 
results and all of mutants were real OX gene disrupted mutants. (Fig. 3-3A) 
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Figure 3-3. (A) Diagnostic PCR and restriction enzyme digestion of the PCR 
products to verify the OX gene disruption mutants. (B) HPLC analysis of the 
metabolites produced by the OX gene disrupted mutants. The HSAF peak produced 
by the wild type strain is indicated with an arrow.  
 
To analyze the metabolites, the mutants were grown in 1/10 TSB medium containing 
gentamicin (20 µg/ml). The procedure for metabolite extraction and analysis was the 
same as described previously78. The results from HPLC showed that none of the OX 
mutants produced HSAF, while the wild type C3 clearly produced HSAF (Fig. 3-3B). 
3-2-2. Generation of OX1, 2 gene deletion mutants   
To construct the OX1 in-frame deletion vector, a 543-bp fragment of OX1 gene with 
an EcoRI site introduced to replace a 27-bp sequence within the gene. This would 
replace 9 amino acid residues (LVEDGRAVG) within a sequence motif that is highly 
conserved among the FAD-dependent oxidoreductases. The following primers were 
used for these experiments. 
P1-OX1-Forw: 5’-AGA CTC GAG AAG CTA GCC ACG CTG C-3’ 
P2-OX1-Revs-fusion: 5’-CGT CTC GAA GAC GAA TTC CAG CTC TAC CAC 
CCG GTC GAC GCG GGT-3’ 
P1’-OX1-forw-fusion: 5’-GTA GAG CTG GAA TTC GTC TTC GAG ACG GTA 
CGG CTC AAG AAC GGC-3’ 
P2’-OX1- Rev: 5’- ACT GGA TCC CGA CTC GCC GGC CGG CA-3’ 
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The following primers that flanked the left arm for homologous recombination were 
used to screen for OX1 single crossover mutants. A 1083-bp fragment was produced 
from the positive colonies. 
P1-OX1 5’-TAA GGA TCC GCC GGC ATG GCC ACC G -3’ 
P2-OX1 5’-ACC ATG ATT ACG CCA AGC-3’  
P3-OX1 5’-TCA CTC GAG TCA GGC GGC CGG AAG C-3’ 
 
Genomic DNA of Lysobacter enzymogenes C3 was used as template to amplify the 
complete OX1 in-frame deletion cassette. The upstream homologous region (left arm, 
LA) was amplified with P1-OX1-For/P2-OX1-Rv-Fusion and the downstream 
homologous region (right arm, RA) was amplified with 
P1'-OX1-For-Fusion/P2’-OX1-Rv. The PCR program for the amplification of both 
arms was as follows: denaturation at 98 ºC for 5 min, followed by 35 cycles of 98 ºC 
for 30 sec, 65 ºC for 30 sec and 72 ºC for 40 sec. Purified PCR products from the first 
PCR reaction served both as template and the primers for extension PCR that runs 30 
cycles of amplification under the same condition in a 20 µl PCR system. Primers 
P1-OX1-For/P2’-OX1-Rv were then added to further amplify the fusion PCR 
products for 20 cycles. The fusion product was subjected to 1% agarose gel analysis. 
The product with the desired size was purified from the gel and served as the template 
to amplify the fusion PCR product for 35 cycles in a 40 µl PCR system. The fragment 
was then cloned into the conjugal vector pJQ200SK as an XhoI/BamHI fragment to 
produce pJQ200SK-OX1 (Fig. 3-4B). 
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Figure 3-4. Scheme for OX1 gene deletion. The replacement cassette was cloned into 
the conjugation vector pJQ200SK through XhoI/BamHI. Red bar represents the EcoRI 
site introduced to the host genome to replace a 27 bp sequence of the original gene. 
Primers P1/P2 were used for single crossover mutant screening. Primers P1/P3 were 
used for double crossover mutant screening.  
 
To construct the OX2 gene in-frame deletion vector, a 536-bp fragment was amplified 
from OX2 gene, with an EcoRI site introduced to replace an 18-bp sequence within 
the gene. This would replace 6 amino acid residues (GGGVGG) within a sequence 
motif that is highly conserved among the FAD-dependent oxidoreductases. The 
procedure for generating OX2 in-frame deletion mutant was identical to that for OX1. 
The following primers pairs were used for these experiments. 
LA RA
LA RA
XhoI BamHIEcoRI
P1 P1-OX1-For P1'-OX1-For-fusion
P2-OX1-Rv-Fusion P2'-OX1-Rv P3
GmR SacB
LA RALA RA
EcoRI
P1
P2
LA RA
P1
P3
LA crossover
RA crossover
Genome of wild type
L. enzymogenes
GmRSacB
pJQ200SK-OX1
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P1-OX2- Forw: 5’-CCA CTC GAG CCC GAC CAT GCC GCA C-3’ 
P2-OX2-Revs-fusion: 5’-TGC GCC GAA TTC GCC AGC GAT GAC GAT CAC 
CCG CGG CGT-3’ 
P1’-OX2- Forw-fusion: 5’-GCT GGC GAA TTC GGC GCA CTG TCC ACC GGC 
GTC TAC GGC-3’ 
P2’-OX2- Revs: 5’-CTT GGA TCC GCG GCG CAG GTC GGC-3’ 
 
The following primers were used to screen for OX2 single crossover mutants. A 
657-bp fragment was produced from the positive colonies. 
N1-OX2 5’-ACC ACG AGG ACC CGA CCA TGC-3’ 
N2-OX2 5’-ACC ATG ATT ACG CCA AGC-3’  
N3-OX2 5’- CCACTCGAGCCCGACCATGCCGCAC -3’ 
 
The OX2 double crossover mutants were screened using primers N1-OX2 and 
N3-OX2, which amplified a 536-bp fragment from the positive mutants. An EcoRI 
digestion of this fragment yielded two products of 161-bp and 375-bp, as expected.  
 
 
 
 
 
 
 
LA RA
LA RA
XhoI BamHIEcoRI
N1 P1-OX2-For P1'-OX2-For-fusion
P2-OX2-Rv-Fusion P2'-OX2-Rv N3
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LA RALA RA
EcoRI
N1
N2
LA RA
N1
N3
LA crossover
RA crossover
Genome of wild type
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GmRSacB
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Figure 3-5. OX2 gene deletion scheme, replacement cassette was cloned into the 
conjugation vector pJQ200SK through XhoI/BamHI. Red bar represents the EcoRI 
site introduced to the host genome to replace a 18 bp sequence of the original gene. 
Primers N1/N2 were used for single crossover mutant screening. Primers N1/N3 were 
used for double crossover mutant screening.  
 
To conjugally transfer pJQ200SK-OX1 and pJQ200SK-OX2 into Lysobacter 
enzymogenes strain C3, the procedure was identical to the previously described. To 
screen the single crossover mutants, the genomic DNA was prepared from 1/10 TSB 
cultures of the individual colonies to serve as templates for PCR reaction. For the 
OX1- deletion mutants, primers P1 and P2 were used to screen the left arm single 
crossover mutants (Fig. 3-4). A 1083-bp fragment was expected from the positive 
colonies. The single crossover mutants of OX2-deletion mutants were identified 
similarly using primers N1 and N2 (Fig. 3-5). A 657-bp fragment was expected from 
the positive colonies. For both PCR reactions, the genomic DNA of wild type 
Lysobacter enzymogenes C3 served as the template for a negative control. No product 
with expected size was observed in the negative control. 
The single colonies identified from single crossover were subjected to liquid cultures 
containing 5% (W/V) sucrose to select for the loss of the vector through a second 
homologous recombination. The single crossover mutants were grown in 1/10 tryptic 
soy broth (TSB) medium for 14 hours. Then the individual cultures were 
re-inoculated into 1/10 TSB (with 1:100 ratio) containing 5% sucrose and 25µg/ml 
kanamycin medium. Aliquots (50 µl) were taken out every 3 hours from this liquid 
culture and spread onto 1/10TSA plates (5% sucrose, 25 µg/ml kanamycin). Single 
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colonies were picked up from the plates and continued to grow in 1/10TSB (5% 
sucrose, 25 µg/ml kanamycin) liquid medium for another 2-5 days. To confirm the 
double crossover mutants, the genomic DNA was prepared from 1/10TSB cultures of 
the individual single colonies to serve as templates for PCR reaction. OX1 double 
crossover mutants were screened using primers P1 and P3, which will amplify a 
1198-bp fragment from the positive mutants. An EcoRI digestion of this fragment will 
yield two products of 736-bp and 446-bp. OX2 double crossover mutants were 
screened using primers N1 and N3, which will amplify a 536-bp fragment from the 
positive mutants. An EcoRI digestion of this fragment will yield two products of 
375-bp and 161-bp. 
3-2-3. Generation of OX3, 4 gene deletion mutants 
(note: I acknowledge Yunxuan Xie for preparing the OX3, 4 gene deletion mutants.)  
To construct the OX3 in-frame deletion vector, primer extension PCR reactions were 
performed to generate a 593-bp fragment of OX3 gene with an EcoRI site introduced 
to replace a 27-bp sequence within the gene. This would delete 9 amino acid residues 
(LVEDDRAVG) within a sequence motif that is highly conserved among the 
FAD-dependent oxidoreductases. The procedure for generating OX3 in-frame 
deletion mutant was identical to that for OX1. The following primers were used for 
these experiments. 
P1-OX3-For 5ʹ′-ATTCTAGATTCCTCCCCTACTTCAACGCCATCCG-3ʹ′  
P2-OX3-Rv-Fusion 
5ʹ′-GCCCGTCGCTCAGGCGGAGAATTCGATCTCCTCGACTTTCGC-3ʹ′  
P1'-OX3-For-Fusion 
5ʹ′-GCGAAAGTCGAGGAGATCGAATTCTCCGCCTGAGCGACGGGC-3ʹ′  
84	  	  
	  
P2'-OX3-Rv 5ʹ′-atctcgagactgcacgttgatgctcgggtggcg-3ʹ′  
 
To construct the OX4 gene in-frame deletion vector, a 525-bp fragment was amplified 
from OX4 gene, with an EcoRI site introduced to replace a 33-bp sequence within the 
gene. This would delete 11 amino acid residues (PFRPGDLVQGF) within a sequence 
motif that is highly conserved among the Zn-dependent alcohol dehydrogenases. The 
following primers pairs were used for these experiments. 
P1-OX4-For 5ʹ′-ATACTAGTGACCGCAAGC ACATGAAGACCGAACG-3ʹ′  
P2-OX4-Rv-Fusion  
5ʹ′-AGGTGCGTGCGCCAGCCGCCGAATTCCGCGTTCGGGCCGGCATCGA-3ʹ′ 
P1'-OX4-For-Fusion  
5ʹ′-TCGATGCCGGCCCGAACGCGGAATTCGGCGGCTGGCGCACGC ACCT-3ʹ′  
P2'-OX4-Rv 5ʹ′-ATCTCGAGAACCAGGGTGCCGATCATGCCCGAGG-3ʹ′ 
 
To conjugally transfer pJQ200SK-OX4 and pJQ200SK-OX3 into Lysobacter 
enzymogenes strain C3, the procedure was identical to OX1 and OX2.  
 
 
 
 
 
              (A)                              (B) 
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Figure 3-6. PCR screening of the OX3 and OX4 in-frame deletion mutants. (A) OX3 
and OX4 deletion double crossover mutants were identified through a PCR reaction 
using primers P1/P3 and N1/N3. The expected size of the PCR product from OX3 
deletion mutants is 702 bp (Lane 1) and yields 349+352 bp fragments upon EcoRI 
single digestion (Lane 2). The expected size of PCR product from OX4 deletion 
mutants is 902 bp (Lane 3) and yields 625+277 bp fragments upon EcoRI single 
digestion (Lane 4). (B) SmaI digestion of OX3 deletion PCR product (Lane 2). The 
expected size of the digestion product is 508+195 bp (Lane 1). 100 bp DNA ladder 
plus is used as the marker. 
 
3-2-4. Metabolites analysis of OX1-4 in-frame deletion mutants 
The verified OX1-4 in-frame deletion mutants were cultured 1/10TSB for metabolites 
analysis. Metabolites were extracted and analyzed according to the method as 
previously described78. A peak with similar retention time of HSAF was obtained 
from OX4 deletion mutant and was further identified using high resolution mass 
spectrometry on Finnigan LCQ.  
3-2-5. Structure identification of the new compounds produced by OX1-4 
deletion mutant 
(note: This part was accomplished by collaboration with Dr. Shen Yuemao at School 
of Life Sciences, Shandong University, Jinan, China.) 
A 10-liter solid LB culture with 1.5% maltose was used for culturing OX4 mutant. 
The solid medium was chopped and extracted with ethyl acetate. Crude extract (5.8 g) 
was fractionated on normal pressure reverse phase C18 column (80 g) and eluted with 
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methanol/water mobile phase starting from 1 liter 60% methanol in water, followed 
by 2 liters 80% methanol in water and 1 liter 100% methanol. Each fraction was 
analyzed on HPLC (Agilent, ZORBAX SB-C18, 4.6×250 mm, 1 ml/min, 318 nm) 
using gradient elution program with mobile phase A (water with 0.005 M TFA) and 
mobile phase B (acetonitrile with 0.005 M TFA) starting from 5% phase B in A in the 
first five minutes, 5% to 40% phase B in A from 5 to 10 minutes, 40% to 60% phase 
B in A from 10 to 15 minutes, 60% phase B in A from 15 to 20 minutes, 60% to 100% 
phase B in A from 20 to 22 minutes, 100% phase B in A from 22 to 24 minutes and 
100% to 5% phase B in A from 24 to 26 minutes. The 80% methanol/water eluent 
(3.4 g, designated as component A) was found to contain  the desired compound. 
Component A was then further fractionated on Sephadex LH-20 (140 g, 3 ml/tube, 8 
s/d), and each fraction was analyzed by HPLC. Desired compound was obtained as 50% 
methanol (0.005 M TFA) eluent by HPLC (Agilent, ZORBAX SB-C18, 9.4×250 mm, 
4 ml/min, 318 nm). 
 
3-3. Results and Discussion 
3-3-1. Construction of OX1 and OX2 in-frame deletion mutants 
The in-frame deletion mutants were constructed through two homologous 
recombination events. To identify OX1-deletion single crossover mutant at left arm, 
primers N1/N2 were used (Fig. 3-4). A 1198-bp fragment was obtained from the 
positive colonies as expected (Fig. 3-7A). The OX1-deletion single crossover mutants 
were identified similarly using primers N1/N2 (Fig. 3-5). A 536-bp fragment was 
obtained from the positive colonies as expected (Fig. 3-7B). To identify both double 
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crossover mutants, diagnostic PCR reactions were performed using primer pair P1/P3 
and N1/N3. Expected size of each PCR product was obtained (Fig. 3-7C-D).  
                   
 
 
             (A)                             (B) 
 
 
 
              (C)                           (D) 
Figure 3-7. PCR screening of the OX1 and OX2 in-frame deletion single and double 
crossover mutants. (A) OX1 deletion single crossover mutants were identified through 
a PCR reaction using primers P1/P2. The expected size of amplicon is 1083 bp. (B) 
OX2 deletion single crossover mutants were identified through a PCR reaction using 
primers N1/N3. The expected size of amplicon is 657bp. (C) OX1 deletion double 
crossover mutants were identified through a PCR reaction using primers P1/P3. The 
expected size of the PCR product from OX1 deletion mutants is 1198 bp (Lane 1) and 
yields 736 and 446 bp fragments upon EcoRI single digestion (Lane 2) (D) OX2 
deletion double crossover mutants were identified through a PCR reaction using 
primers N1/N3. The expected size of the PCR product from OX2 deletion mutants is 
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536 bp (Lane 3) and yields 375 and 161 bp fragments upon EcoRI single digestion 
(Lane 4,5). 
 
3-3-2. Metabolites analysis of OX1-4 in-frame deletion mutants 
Verified OX1-4 deletion mutants were cultured in 1/10 tryptic soy broth in which 
wild type C3 produces large quantities of HSAF. Metabolites of the wild type C3 and 
the four mutants were analyzed by HPLC. OX1-3 deletion mutants did not produce 
HSAF and its intermediate compounds, while OX4 deletion mutant produced a 
compound with similar retention time to HSAF (Figure 3-8A). High resolution mass 
spectrometry analysis showed that the compound had two mass units smaller than 
HSAF (Figure 3-8B). The structure of this compound was determined by 1H-NMR 
and 13C-NMR to be alteramide A (5) (Figure 3-1). These results suggested that the 
OX genes are involved in HSAF biosynthesis and are part of the HSAF gene cluster.  
(A) 
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(B) 
 
 
 
 
 
 
Figure 3-8. (A) HPLC analysis of the metabolites produced by the four OX gene 
in-frame deletion mutants. The new compound produced by the OX4 mutant and the 
HSAF peak produced by the wild type strain are indicated with an arrow. (B) MS 
analysis of the peak at ~22 minute in the OX4 mutant in (A).  
 
3-4. Summary and final remarks 
HSAF represents a new family of antifungal compounds with a novel mechanism of 
action and distinct structural features, including a 5,5,6-tricyclic system fused with a 
17-membered macrolactam that includes the tetramic acid moiety. These features 
make HSAF an interesting target to study its biosynthetic mechanism. Based on 
sequence annotation of the HSAF gene cluster, we first proposed that a single 
modular PKS could synthesize two polyenes that joint together by the amino acid 
ornithine via two amide bonds. Through co-operation with the 6 redox enzymes, the 
polyene-tetramate-polyene intermediate will finally be cyclized and tailored into 
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HSAF or analogs. In this work, we defined the boundary of HSAF biosynthetic gene 
cluster, which suggested that all OXs may be involved in HSAF production, although 
only 2 redox genes are present in the ikaguramycin biosynthetic gene cluster.  
Besides these 6 redox genes, ORF 1 and 10 are also considered to be part of the 
HSAF biosynthetic core genes. ORF 1 encodes a putative major facilitator 
superfamily transporter, whereas ORF 10 encodes a putative TonB-dependent outer 
membrane receptor (Figure 3-2). These two genes might not be essential for 
biosynthesis of HSAF core structure, but are likely to be involved in HSAF transport 
and regulation. Together, these results indicate that the region between ORF1 and 
ORF10 makes the minimal gene cluster of HSAF biosynthesis. 
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Chapter 4: In vitro Characterization of Redox Enzymes in HSAF Biosynthetic 
Pathway 
Portions of this chapter were reported (RSC Advances. 2015, 5, 11644-11648) and are 
reproduced with the permission of the publisher111. 
4-1. Background and significance 
Polycyclic tetramate macrolactams are identified by using a combination of small 
molecule chemistry, biosynthetic analysis, and genome mining in diverse bacteria. 
The PTM group emerges as a new class of natural products with a distinct structure 
and a new mode of action. The most striking feature of the PTM in biosynthesis, 
where only a single hybrid PKS-NRPS is sufficient for the synthesis of the 
characteristic PTM scaffold26, 76. The results presented in chapters 2 and 3 showed 
that a single-module PKS is responsible for the biosynthesis of two separate 
polyketide chains. The hybrid PKS-NRPS for HSAF biosynthesis has a typical 
modular organization, including KS-AT-DH-KR-ACP for the PKS portion and 
C-A-PCP-TE for the NRPS portion. There is no obvious remnant of an inactive 
enoylreductase (ER°) domain or a methyltransferase (CMeT) domain, as seen in 
several iterative fungal PKS-NRPS with the similar organization, such as PKS for 
tenellin, lovastatin and compactin112, 113. Although this type of iterative PKS-NRPS is 
commonly seen in fungi, it is not known in bacteria until recent years. The phylogenic 
study also suggested that the PTM iPKS evolves not far from aromatic iPKS (Figure 
1-2). 
As shown in Figure 3-2, the HSAF PKS-NRPS is flanked by six redox genes, four 
NADP/FAD-dependent oxidoreductase (OX) genes on the left and a 
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hydroxylase/sterol desaturase gene and a NADP/FAD-ferredoxin reductase gene on 
the right. The disruption or in-frame deletion of the PKS-NRPS, OX1, OX2, or OX3 
eliminated HSAF production, whereas the OX4 mutant and hydroxylase/desaturase 
mutant produced putative precursor/shunt products 77 ,78.  
The objective here is to express and purify the redox enzymes, characterizing the 
enzymatic reactions, and reconstitute HSAF biosynthesis using the enzymes and 
substrates. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Proposed mechanism of redox enzymes participate in HSAF tailoring78. 
 
We have already shown that the NRPS module catalyzes the formation of two amide 
bonds between acyl-SNAC and the two amino groups of ornithine, as well as the 
formation of the tetramic acid unit, to produce a product (see Fig. 2-5 in Chapter 2) 
similar to polyene-tetramate-polyene intermediate 3 in Figure 4-1. In the previous 
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experiments, we used saturated acyl chains for the ease of substrate preparation78. 
However, the nascent products of the PKS are polyenes (1 and 2 in Figure 4-1) and 
the NRPS uses the polyene acyl-S-PKS as substrates to condense with ornithine 
(Figure 4-1). We propose the PKS-NRPS cooperates with the redox enzymes to tailor 
the polyene chains of 3 into the tricyclic system of HSAF. The 
polyene-tetramate-polyene feature may help form a relatively rigid scaffold and bring 
together the alkene functionalities in close proximity to allow intramolecular 
cyclizations to take place. One issue here is the configuration of the alkenes. The 
structure of HSAF suggests that three of the alkenes need to be in cis configuration 
(Figure 4-2). PKS DH domains usually generate a trans double bond, although some 
can make a cis double bond 65, 114. As only a single DH domain is present, we propose 
all the double bonds in 1 and 2 are in the trans form and three of them are 
subsequently isomerized to the cis form in 4. No alkene isomerase-like enzyme is 
present in the cluster. However, flavin-dependent redox enzymes could catalyze the 
isomerizations 115, perhaps via a reversible hydrogenation- dehydrogenation. One or 
more of the OX enzymes in the cluster may be involved in the isomerizations.  
Next, through two reductive intramolecular cycloaddition reactions, one [2+4] and 
one [2+3], 4 is converted to 5 and then 6. “Diels-Alderase” activity has been observed 
in the biosynthesis for several fungal polyketides/peptides, such as lovastatin, 
solanapyrone A, macrophomic acid, and spinosyn A116-122. In the HSAF type of 
compounds, because a reduction is also needed in order to form the unusual ring 
system, we propose both the PKS-NRPS and the redox enzymes cooperate in the 
cyclizations (Figure 4-1). The substrate specificity of the redox enzymes may also 
play a key role in determining the chain length and reduction level of the initial PKS 
products 1 and 2. The cycloadditions are apparently stereospecific, resulting in nine 
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chiral centers. It should be noted that the cycloadditions could precede the tetramic 
acid formation, while the intermediate is still bound on NRPS. 
In addition to cycloaddition, a possible route to ring formation is via epoxide opening, 
followed by reductive coupling. The HSAF gene cluster does not contain a candidate 
epoxidase or epoxide hydrolase, so this possibility may be less likely. In summary, 
there are many very intriguing aspects in the proposed biosynthetic mechanism.  
We have established the methods for PKS and NRPS in vitro reactions. The in vitro 
reactions for polyketide-peptide biosynthesis combine ornithine, acetyl-CoA, 
malonyl-CoA, ATP and NADPH, with various combinations of HSAF enzymes. To 
test the activity of the redox enzymes, we will include the redox enzymes, 
individually or in various combinations, in above reaction mixtures. The expectation 
is that the PKS-NRPS-synthesized product like 3 will serve as in situ substrate for the 
redox enzymes. By including various combinations of enzymes, we investigated the 
activity of individual enzymes. Additionally, chemically synthesized polyene 
acyl-SNAC, mimics of 1 and 2, were used in the tests. By using acyl-SNAC (Figure 
4-2) with various chain lengths and reduction levels, the specificity of the enzymes 
will be revealed.  
 
4-2. Materials and Methods   
4-2-1. Strains, Vectors, Chemicals and Molecular Biology Agents  
Escherichia coli DH5α was used as the host for general plasmid DNA propagation. E. 
coli BL21 was used for protein expression. Vector pANT841 was used for general 
cloning, vector pET28a was used for protein expression in E. coli BL21, and vector 
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pET32b, pBAD-myc-His, pQE60, pMAL, pGEX-6p-1, pYES were tested to increase 
the protein solubility. Chemicals were purchased from Sigma or Fisher Scientific. 
PCR primers were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). 
Kits for plasmid preparation and DNA extraction were from Qiagen (Valencia, CA). 
Standard molecular biology methods were used for all other DNA manipulations.  
4-2-2. OX1-4 expression in E. coli 
To construct the expression vector, OX1-4 genes were amplified by PCR using Taq 
DNA polymerase and the genome extracted from L. enzymogenes OH11 as template. 
The primers are listed in table.  
Primer design: 
OX1-Rev-XhoI: 5’- TCACTCGAGTCAGGCGGCCGGAAGC -3’ 
OX1-Forw-BamHI: 5’-TAAGGATCCGCCGGCATGGCCACCG-3’ 
OX2-Rev-HindIII: 5’- TCAAAGCTTTCAGACGATGGTGGCG-3’ 
OX2-Forw-BamHI: 5’-TAAGGATCCGCGCGCGATAACGGCC-3’ 
OX3-Rev-XhoI: 5’- TCACTCGAGTCATGTGCTTGCGGTC -3’ 
OX3-Forw-BamHI: 5’-TAAGGATCCATGCCGAGCGGCAAGC-3’ 
OX4-Rev-XhoI: 5’- TCACTCGAGTCACACCCGCACCAGCAC -3’ 
OX4-Forw-BamHI: 5’-TAAGGATCCATGAAGACCGAACGTTG-3’ 
The PCR fragment was digested and cloned into pANT841 at the same sites. The 
constructs were sequenced, and the result showed that all the OX1-4 sequences were 
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correct. The OX genes were released from pANT841 and cloned into expression 
vector pET28a. To express the OXs, each of the pET28a constructs was introduced 
into E. coli BL21 (DE3). Single colonies were inoculated in 3 ml of liquid LB 
medium containing kanamycin (50 µg/ml) and incubated in a shaker (250 rpm) at 
37 °C overnight. The overnight culture was added to 50 ml fresh LB medium and 
incubated in a shaker (250 rpm) at 37 °C until the cell density (OD600) reached 0.6. To 
induce the expression of the OXs, IPTG (0.1 mM) was added to the culture, and the 
cells were allowed to grow at the same conditions for another 3 h. To prepare the 
soluble fraction, the cells were harvested and resuspended in 2 ml of Tris-HCl buffer 
(250 mM NaCl, 100 mM LiCl, 50 mM Tris). The cell suspension was treated with 
lysozyme (1 mg/ml) and sonicated five times on ice. The soluble fraction of protein 
extracts was loaded onto a Ni-NTA column, which was previously equilibrated with 
Tris buffer containing 10 mM imidazole. The column was washed three times with 
the buffer containing 20 mM imidazole, and the His6-tagged protein was eluted twice 
with 200 µl of Tris buffer containing 250 mM imidazole.  
Other expression vectors were also used to increase the protein solubility, including 
pBAD-myc-His, pQE60, pMAL, and pGEX-6p-1. The expression methods are 
according to the standard protocols.  
4-2-3. Redox enzymes expression in yeast 
The four redox genes OX1-4 were amplified by PCR using Taq DNA polymerase and 
the cosmid COS4-1 as template, which contains part of the HSAF gene cluster. The 
OX1, OX3 and OX4 fragment were digested with XhoI and BamHI; the OX2 
fragment was digested with HindIII and BamHI. The fragments were cloned into 
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pET28a vector at the same sites. The four redox genes were released from pET28a 
and cloned into expression vector pYES2.   
To express the redox enzymes, the pYES2 constructs were introduced in S. cerevisiae 
strain INVSc1. The transformation and expression were followed the instruction from 
Invitrogen (Cat. no.V825–20). The cells were pelleted and resuspended in microsome 
extraction buffer (50 mM Tris, 1 mM EGTA, 1 mM β-mercaptoethanol, 1 mM 
phenylmethylsulfonyl fluoride, 2 µg/mL pepstatin A, pH 7.5) (2 mL/g). After adding 
glass beads, the cells were vortexed 60 seconds for 6 cycles. The glass beads were 
filtered out, followed by centrifuge at 5000 × g for 10 min. The supernatants were 
centrifuged at 100,000 × g for 1 hour using OptimaTM MAX-XP Ultracentrifuge 
(Beckman Coulter, CA). Microsomes were suspended at 1 mL/g in the microsome 
extraction buffer with 33% glycerol and stored at -80 °C. 
4-2-4. In vitro assay of OX1-OX4 microsomes using alteramide A as substrate 
The in vitro activity assay comprises 400 µM alteramide A, 1 mM FAD, 2 mM 
NADH, 50 mM NaCl, and 10 µg OX1-4 microsomes, in 50 mM Tris·HCl buffer (pH 
8.0). The control reactions used micorsomes extracted from yeast cells which host 
pYES2 blank vectors. After continual incubation for 2 h at 37 °C, the reactions were 
stopped by adding an equal volume of ethyl acetate. The mixtures were centrifuged at 
13,200 rpm for 5 min, and the top layers were transferred to new tubes. The solutions 
were air dried, and the residues in the tubes were re-dissolved in 150 µl methanol. 
The methanol solutions were centrifuged, transferred to new tubes, and dried again.  
In the in vitro HSAF biosynthetic reaction, the system described in Chapter 2 was 
incubated with the microsomes of the four OXs, 10 µg each, together with 1 mM 
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FAD, 2 mM NADH and 0.1 mM BSA. After incubation for another 2 h at 37 °C, the 
reactions were stopped and extracted using the same method described above.  
Finally, the products of the reactions were re-dissolved in 20 µl methanol and 
analyzed by LC-MS (HPLC: Agilent Technologies, 1220 Infinity LC; MS: Finnigan 
mat, LCQ). LC-MS column was Alltima C18LL (5 µ, 1.0 mm × 250 mm). Solvent A 
was H2O containing 0.1% formic acid; Solvent B was acetonitrile containing 0.1% 
formic acid. The flow rate was 50µl/min, with a binary gradient system (0-15 min, 
5%-45% B gradient; 15-35 min, 45% B to 90% B gradient; 35-46 min, 90% B to 100% 
B gradient; 46-55 min, 100% B; 55-56 min, 100% B to 5% B gradient; 56-66 min, 5% 
B). 
4-2-5. Synthesis of a 2,4,6,8,10-dodecapentanoic acid thioester 
The synthesis of a 2,4,6,8,10-dodecapentanoic acid thioester was published on RSC 
Advances by Andrew Olson, Haotong Chen, Liangcheng Du, and Patrick Dussault111.  
 
 
 
 
 
 
 
Figure 4-2. Synthesis of all-E-2,4,6,8,10-dodecapentenoate SNAC thioester. 
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4-2-6. In vitro assay for the activity of NRPS using the pentaenoic acid thioester 
substrate 
NRPS needs to be converted to its holo-form by a promiscuous 
4'-phosphopantetheinyl transferase (PPTase), Svp, by incubating with coenzyme A. 
The holo-NRPS was obtained by incubating protein (3 µM) and CoA (0.83 mM) with 
Svp (5.6 µM) in a 60 µl reaction containing Tris-HCl (100 mM, pH 8.0), MgCl2 (10 
mM), and TCEP (0.5 mM). Reaction was incubated at 37 °C for 2 h. Finally, the 
reaction mixture was added a 40 µl solution containing L-Orn (1.5 mM), ATP (3 mM), 
Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), NaCl (50 mM), EDTA (0.1 mM), and 
TCEP (0.5 mM). A reaction without NRPS served as the control. The cell free extract 
(CFE) extracted from ΔPKS mutant78 was considered to provide crude redox enzymes, 
which catalyse the 5,5,6-tricyclic ring system formation in HSAF, coupled with 0.5 
mM FAD/NADH. The pentaenoate thioester was added right away in a dark room, to 
make a final concentration of 0.5 mM. After continual incubation overnight at 30 °C, 
the reactions were stopped by adding 150 µl of 0.2 mM TCA in methanol and were 
frozen at -20 °C for 30 min. The mixtures were centrifuged at 13,200 rpm for 20 min 
in a desktop Eppendorf centrifuge, and the supernatants were transferred to new tubes. 
The solutions were dried in a Speed-Vac, and the residues in the tubes were 
re-dissolved in 20 µl methanol, and analyzed by Agilent LC-1200 (Santa Clara, CA) 
connected to a 2.1 x 100 mm Symmetry ODS column from Waters (Milford, MA) 
and a Triple Quadrupole Mass Spectrometer model 4000 QTrap from ABSciex 
(Framingham, MA) operating in either single quadrupole (Q1), enhanced mass 
spectrum (EMS), MS/MS or multiple reaction monitoring (MRM) modes.  The 
samples were injected onto the column and a gradient from 98% mobile phase A (0.1% 
formic acid in water, J.T. Baker) to 60% B (0.1% formic acid in acetonitrile, Acros 
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Organics) was run over 15 minutes, followed by 5 minutes of 98% B and 5 min of 98 % 
A, all at a flow rate of 0.25 mL/min. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. A proposed pathway of in vitro biosynthesis of HSAF from 
E-2,4,6,8,10-dodecapentenoate SNAC thioester (9). 
 
4.3. Results and discussion 
4-3-1. Redox enzymes expression 
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Figure 4-4. SDS-PAGE of OX1-4 expressed in E. coli under different expression 
conditions. M, markers; BI: cell lysate before induction as control. 30, 37: induction 
temperature is 30 or 37 °C. 3h, 6h: the induction time is 3 or 6 hours. 
 
Since the expressed proteins all ended up in the inclusion bodies, the conditions were 
optimized, including temperature and induction time, together with switching the 
IPTG concentration. Other plasmids were used to improve solubility. 
 
 
 
 
 
 
 
 
                 (A)                                 (B) 
Figure 4-5. (A) SDS-PAGE of the OX1 expressed in E. coli under induction of 
different concentration of IPTG. M, markers; BI: cell lysate before induction as 
OX1	   OX2	   OX3	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control. 0.1, 0.3, 0.5: concentration of IPTG is 0.1 mM, 0.3 mM and 0.5 mM. S: total 
soluble proteins after sonication; P: precipitate portion after sonication. 
(B) SDS-PAGE of the OX1-3 in pGEX-6p-1 vector expressed in E. coli under 
induction of different concentration of IPTG. M, markers; BI: cell lysate before 
induction as control. 0.1, 0.5, 1: concentration of IPTG is 0.1 mM, 0.5 mM and 1 mM. 
S: total soluble proteins after sonication; P: precipitate portion after sonication.  
 
The results showed that OX1-4 expressed in E. coli were present predominantly in the 
inclusion bodies. To circumvent this problem, OX1-4 was expressed in yeast, and 
microsomes were extracted and used in in vitro assay. 
4-3-2. In vitro reaction of OX4 using alteramide A as substrate 
Recently, the Zhang group reported the enzymatic mechanism for the formation of the 
inner 5-membered ring and demonstrated the polyketide origin of the ikarugamycin 
skeleton81. A three-gene-cassette ikaABC from the marine-derived Streptomyces sp. 
ZJ306 is sufficient for conferring ikarugamycin production in a heterologous host. 
IkaC catalyzes a reductive cyclization reaction to form the inner five-membered ring 
by a Michael addition-like reaction.  
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Figure 4-6. The proposed mechanism of IkaC, a redox enzyme from ikarugamycin 
gene cluster81. 
In the HSAF gene cluster, OX4 gene has been predicted to encoding an alcohol 
dehydrogenase zinc-binding protein, which has the greatest similarity to ikaC, thus 
becoming a candidate for catalyzing the last ring closure. Alteramide A was isolated 
from the wild type and OX4 disruption mutants, which has the bi-cyclic ring system 
(Figure 3-1). Although the configuration of H on 12-C is different from HSAF, it 
could still possible to serve as an alternative substrate for OX4. The molecular 
modeling using SWISS MODEL indicated a good docking of alteramide A with OX4 
(Identity: 32%, Score: -146) using NADPH-dependent oxidoreductase as template 
(PDB accession number: 2J3I). Thus this compound was used in in vitro activity 
assay for the 4 OX enzymes. 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. Molecular modeling of OX4 with alteramide A as ligand. Template: 
NADPH-dependent oxidoreductase123. 
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Figure 4-8. The proposed mechanism of last ring closure in HSAF biosynthesis. 
 
In the in vitro activity assay, 400 µM alteramide A was incubated with 10 µg OX4 
microsomes, together with 1 mM FAD, 2 mM NADH, 50 mM NaCl, in 50 mM 
Tris·HCl buffer (pH 8.0). The control reaction used micorsomes extracted from yeast 
cells which host pYES2 blank vectors. After the reactions were stopped, the extracts 
were analyzed by HPLC and MS analysis. Although the HPLC chromatogram 
showed no obvious difference between the control and the real reaction, with the time 
growing, the HPLC peaks revealed several reproducible differences in real reaction 
group.  
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Figure 4-9. HPLC analysis of in vitro assays. (A): Alteramide A standard. (B): ΔKR 
mutant which has no HSAF or analog produced. (C): Control reaction w/o OX4 added. 
(D): Real reaction with OX4 after 10 hours incubation. (E): Real reaction with OX4 
after 20 hours incubation. 
 
The HPLC analysis showed that alteramide A is being consumed during the 
incubation, but unfortunately, new HSAF-like peaks are not observed by HPLC.  
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4-3-3. In vitro assay for the activity of NRPS using the pentaenoic acid thioester 
substrate 
Although it was proved that the NRPS module catalyzes the formation of two amide 
bonds between acyl-SNAC and the two amino groups of ornithine, as well as the 
formation of the tetramic acid unit, to produce a product (see Figure 2-5 in Chapter 2) 
very similar to intermediate 3 (Figure 4-1) 82, the nascent products of the PKS (1 and 
2) and the nascent substrates of NRPS, acyl-S-PKS, has not been added and evaluated 
in the in vitro reaction system. To examine the activity and selectivity of NRPS 
toward different substrates, the native substrate all-E-2,4,6,8,10-dodecapentenoate 
SNAC thioester was chemically synthesized and added into the in vitro reaction.  
The expected final product is the polyene-tetramate-polyene shown in Figure 4-1, and 
this polyene-tetramate-polyene intermediate was previously obtained by incubating 
the hybrid PKS-NRPS with a series of co-enzyme and substrates26. But this 
intermediate is very unstable and difficult to be isolated under normal condition. The 
OXs, which are supposed to catalyze the ring closure reactions to form a rigid 
5,5,6-tricyclic ring system, were added into the reaction, so that the resulting products 
with the ring system should be more stable and easier to be detected. 
Pentaenoate thioester 9 was incubated with the NRPS protein, ornithine, 
phosphopantetheinyl transferase, CoA, crude redox enzymes, ATP, and FAD/NADH 
at 30 °C, and the products were compared with those resulting from an incubation 
conducted in the absence of the NRPS protein. LC-MS analysis found a variety of 
products having a mass consistent with the predicted HSAF precursor or analogues 
(Figure 4-12), and the compounds with spontaneously formed amide bond (Figure 
4-14). However, no HSAF was observed.  
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Figure 4-10. Proposed NRPS-catalzyed biosynthesis of (A) tetraketide, (B) 
pentaketide, and (C) hexaketide polyene tetramate intermediates using the 
corresponding chemically synthesized SNAC substrates. 
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Figure 4-11. Structure of possible intermediates produced in the in vitro reactions 
after cyclization by redox enzymes. 
 
Figure 4-12. LC-MS result of the in vitro reactions. The pointed peaks showed the 
corresponding masses of the predicted possible structures.  
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Figure 4-13. Possible structures and expected masses of the compounds with 
spontaneously formed amide bond. 
 
 
 
 
Figure 4-14. Mass spectrum of the detected compounds with automatically formed 
amide bond.  
 
4-4. Summary and final remarks 
The experiments described in this chapter support a new mechanism for the 
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iterative PKS-NRPS, in cooperating with a cascade of redox enzymes, to synthesize a 
complex and highly modified polycyclic tetramate macrolactam. OXs in CFE do have 
activities. They are able to catalyze the ring closure. NRPS also shows a broad 
specificity toward the substrates with different chain length, and it’s able to catalyze 
the two amide bonds formation and tetramate acid ring formation. The novelty is, 
very few Diels-Alder-like redox enzymes have been recognized in fungi or bacteria, 
representing a new way by which nature assembles a complex and distinct molecular 
scaffold. The mechanistic understanding of the biosynthetic process potentially 
expand approaches to other bioactive PTM. A big problem here is that it’s hard to 
obtain soluble OX enzymes. Further efforts will be needed to improve the solubility 
of the proteins. Another problem is that the polyene-tetramate-polyene intermediate is 
very unstable. Without the ring structure formed by OXs enzymes, this intermediate is 
difficult to isolate and characterize. 
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Chapter 5: Fatty Acids Activation and Selection in the Biosynthesis of 
WAP-8294A, a Group of Anti-MRSA Cyclic Lipodepsipeptides 
5-1. Background and Significance 
The over-reliance on limited drug targets has led to the rapid emergence of 
anti-infectious drug resistance. For instance, the recent outbreak of “NDM-1 
symptoms” (short for New Delhi Metallo-beta-lactamase) in 2009 is the result of a 
superbug that are resistant to many antibiotics, including those drugs that are reserved 
as the last resorts for treatment of infectious disease defense124. This is a 
life-threatening concern because few new antibiotics have been developed in the past 
four decades. For antibacterial drugs, since the introduction of fluoroquinolones in the 
1960s, there was an almost four-decade innovation gap in new antibiotic discovery 
until linezolid was introduced in 2000 and daptomycin (Cubicin®) in 2003. Serious 
threats, such as the multi-drug resistant NDM-1, demand new antibacterial agents 
with novel structures and activities. Especially, nosocomial infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA) in hospitals have become a 
serious clinical problem125. Thus, it is imperative to continue the discovery and 
development of new antibiotics126.  
Natural products (NPs) are the most prolific source of bioactive compounds, 
especially anti-infective and anti-cancer agents. Our lab has been using Lysobacter 
enzymogenes strain C3 and OH11 as a new source for bioactive NP discovery26, 76. 
Figure 5-1 are NPs isolated from various Lysobacter species. Both lysobactin and 
tripropeptins exhibit strong anti-MRSA and anti-VRE (vancomycin resistant 
Enterococcus) activities92, while dihydromaltophilin (HSAF) discussed in the 
previous chapters exhibits strong inhibitory activities against a wide range of fungi. 
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WAP- 8294A is a family of cyclic lipodepsipeptides originally isolated from 
Lysobacter staphylocidin, that display anti-MRSA activity125, 127-129. This group of 
compounds exhibits up to 14-fold greater antibacterial activity than vancomycin, 
appear to exert their cytotoxic effect by selective interactions with phospholipids in 
the target cell membrane resulting in membrane damage129. Among the member of 
this family of NPs, , WAP-8294A2 had reached Phase-I/II clinical studies.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1. Natural products isolated from various Lysobacter species110. The figure 
is reproduced with the permission of American Society for Microbiology 
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We reported the identification and characterization of the WAP- 8294A2 biosynthetic 
gene cluster from L. enzymogens strain OH11110. After genome sequencing of L. 
enzymogenes OH11, we found at least nine clusters which contain genes for 
polyketide synthase and nonribosomal peptide synthetase (PKS-NRPS). Through 
genome annotation and a series of gene disruption experiments, a total of 45 domains 
that make up 12 NRPS modules were identified to encode enzymes involved in 
WAP-8294As core structure biosynthesis (Figure 5-2)110.  
 
 
 
 
 
 
 
Figure 5-2. Putative biosynthetic gene cluster of WAP-8294As110. The figure is 
reproduced with the permission of American Society for Microbiology. 
 
Disruption mutants of the NRPS genes lost the inhibitory activity against B. subtilis, 
suggesting that the NRPS cluster is likely to be a major contributor to the antibacterial 
activity of L. enzymogenes. Total metabolites extracted from the mutants revealed the 
absence of a major peak, which presents in the wild-type strain; this peak was then 
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determined to be WAP-8294A2 by mass spectrometry and NMR analysis. The results 
demonstrated that the NRPS cluster is responsible for the biosynthesis of 
WAP-8294A2, as well as other members in the WAP family that differ only in the 
length of the acyl side chain.  
Compounds in the WAP-8294 family differ mainly in the nature of the 3-hydroxy 
fatty acyl moiety, which all compounds in the family possess. In most cases, the free 
fatty acids are activated as CoA thioesters, necessitating the existence of an enzyme to 
activate and introduce the 3-hydroxy fatty acid chain into the peptide. Such acyl-CoA 
ligase enzymes are often located in the vicinity of the NRPS cluster130. While the 
amphi-enterobactin130, daptomycin131 and calcium-dependent antibiotic (CDA)132 
gene clusters all contain a dedicated acyl-CoA ligase and an ACP loading domain for 
the activation and incorporation of the fatty acyl side chain, the surfactin133 and the 
WAPS cluster do not contain neither an ACL, nor an ACP domain in front of the 
WAPS assembly line, suggesting that the WAP-8492A biosynthetic pathway likely 
recruits an ACL outside the gene cluster (in trans). Generally, this type of in trans 
ACLs exhibits a broad specificity and is able to function redundantly134. This could be 
the reason that WAP-8492A compounds share a common amino acid composition and 
only differ in the length of the fatty acid side chain. These features could turn ACLs 
into interesting targets for production of novel WAP analogs by genetic 
engineering135. The hypothesized pathway starts with the activation of the 3-hydroxy 
fatty acid into acyl-S-CoA by the action of an in trans ACL110. A type III C domain is 
present at the N- terminus of the WAPs NRPS, which is a common feature found in 
NRPSs dedicated to cyclic lipopeptides, such as surfactin, daptomycin and CDA. In 
the biosynthesis of such lipopeptides, the activated acyl-S-CoA can directly serve as 
substrate to be incorporated into the peptide136 or, alternatively, can be transferred to a 
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dedicated acyl carrier protein (ACP) as acyl-S-ACP, which is then incorporated into 
the peptide.  
The aim of this work is to determine the activation and mechanism for incorporation 
of fatty acid side chain in the biosynthesis of WAP-8294A. Here, we show that 
several ACLs play an important role in the initiation process. We used chemically 
synthesized fatty acids as substrates, providing evidence both in vitro and in vivo that 
the ACL-6 is the dominate enzyme that activates 3-hydroxy-7-methyloctanoic acid 
and initiates WAP8294A2 formation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Proposed biosynthetic pathway of WAP-8294As110. The figure is 
reproduced with the permission of American Society for Microbiology. 
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5-2. Materials and methods 
5-2-1. Bacterial strains, plasmids, and general DNA manipulations  
Chemicals used in this study were purchased from Fisher Scientific or Sigma. 
Oligonucleotide primers for PCR were synthesized by Fisher. Plasmid preparation 
and DNA extraction were carried out with Qiagen kits (Valencia, CA), and all other 
DNA manipulations were carried out according to standard methods. Ni-NTA agarose 
was purchased from Qiagen (Valencia, CA). Escherichia coli strain XL Blue was 
used as the host for general plasmid DNA propagation, and the cloning vector was 
pANT841. Vector pET28a was used for protein expression in E. coli BL21 DE3. E. 
coli S17-1 was used as the conjugal strain. Lysobacter enzymogenes and other 
bacterial strains were grown in Luria- Bertani (LB) broth medium, 1/10-strength 
tryptic soy broth (1/10 TSB, Sigma) or NYGB/A medium. EnzChek Pyrophosphate 
Assay Kit was purchased from Sigma. 
5-2-2. Generation of gene disruption mutants  
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117	  	  
	  
Figure 5-4. Strategy of gene disruption by single crossover leading to plasmid 
insertion. 
 
To construct the plasmid vectors for gene disruption, an internal fragment was 
amplified from each of the ORFs using the primer pairs described below. Genomic 
DNA from the wild type Lysobacter enzymogenes OH11 served as the PCR template. 
The homologous regions of these ACLs were amplified by PCR and introduced into 
the conjugation vector pJQ200SK to produce seven versions of pJQ200SK-ACLs. 
Each of the pJQ200SK-ACL constructs was transformed into E. coli S17-1, which 
was mated with L. enzymogenes OH11 for conjugal transfer of the vectors. The 
positive colonies grown on LB plates containing gentamicin (20 µg/ml) were picked 
up and inoculated into liquid cultures containing gentamicin. Genomic DNA was 
prepared from each of the cultures, and diagnostic PCR were performed to identify 
mutants that resulted from a homologous recombination. To screen the ACL gene 
disruption mutants, PCR were performed using the diagnostic primers listed in Table 
5-1, which would amplify correct fragments when mutants resulted from a 
homologous recombination, but not from the wild type or mutants resulted from a 
random insertion of the construct (Figure 5-4).  
Table 5-1. Primers used in this paper 
Primers for 7 ACL genes disruption 
Name No. 
Fragment 
Length 
Primers 
ACL-1 LysEGL003270 496bp Forward: TTACTCGAGTCAATCCCAAGCTCAAGC 
   
Reverse: TATGGATCCTAGTTGTGCAGCACCAGC 
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ACL-2 LysEGL000201 488bp Forward: TAACTCGAGATTCCAGCCACGAA 
   
Reverse: TATGGATCCATGCTTGAGGATGCGTTC 
ACL-3 LysEGL000048 579bp 
Forward: 
TAACTCGAGAGCTCGAACTCAAGAAGG 
   
Reverse: AATGGATCCTGACGATGATTTCCTGGC 
ACL-4 LysEGL000406 555bp Forward: ATCCTCGAGTTCTTCCTGCTGATGTTC 
   
Reverse: TATGGATCCTAGCGCATCGTGCAACT 
ACL-5 LysEGL003038 604bp Forward: TATCTCGAGTCAACACCAATCCGATGT 
   
Reverse: TAG GGATCCTTTTCCTGCAGTTCCTTC 
ACL-6 LysEGL001572 630bp 
Forward: 
TAACTCGAGCACTCCGAAAACCATCTG  
   
Reverse: AATGGATCCTCGTCGTGGAAGATCG 
ACL-7 LysEGL003969 700bp Forward: TAACTCGAGGATCTCGCATCGCAAC 
   
Reverse: TATGGATCCGGTCGTGAGGTAATAGC 
 Primers for 7 ACL genes expression 
Name Fragment Length 
Protein size 
(Da) 
Primers 
ACL-1 1677bp 58677.4 Forward: ATAGAATTCAGCCCGACCGTCAGCC  
   
Reverse: AGGAAGCTTAGCACAACAGGACCC 
ACL-2 1635bp 58767.3 Forward: AACGAATTCATGCTCTCCCGACTGA 
   
Reverse: TATCTCGAGCGGAGCGAAAGGGAAG 
ACL-3 1737bp 60454.5 Forward: TTAGAATTCTGGGCGCTCGTATCC  
   
Reverse: ATACTCGAGCGCTTTCACCGCAATG 
ACL-4 1695bp 59778.6 Forward: TATGAATTCCCACCCGCTCGGCTGA 
   
Reverse: TAAAAGCTTCAGTGCCGCCTCTCAA 
ACL-5 1677bp 61084.6 Forward: TATGAATTCAGTTTGAACCGTCCGT 
   
Reverse: TATAAGCTTACCCATGCTCACGCGT 
ACL-6 1395bp 47157.1 Forward: TAAGAATTCCAACAACGAATCGCTG 
   
Reverse: ATGAAGCTTATGACCCGGGATTTAT 
ACL-7 1713bp 58643 Forward:TAAGAATTCTCAAGGACCGATCGAA 
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Reverse: ATTAAGCTTCCATCTGCAGGGTCAT 
Primers for construction of ACL-6 deletion mutant 
ACL-6 upstream 412bp ATC GTC GAC CTT CTT CCT GCA A 
   
CTC GGATCC TTC GTT GTT GAG G 
ACL-6 downstream 280bp CTA GGATCC CCT GAA GCA GAT C 
   
GCG TCT AGA TGA GCG GTT CCA T 
Diagnostic Primers 
No. Forw-diagnostic primer sequence Expected length 
ACL-1 TGTACCACGACAAATCCATCC 632bp 
ACL-2 TGATGATCGTGCACACCTCC 903bp 
ACL-3 AGATAGATCCCGACGCGCTG 796bp 
ACL-4 TGTGCAACATCGCCGC 840bp 
ACL-5 AGCTCAAGCTCAAGAAGGGC 770bp 
ACL-6 ATCGACATGCTGGCGTTG 906bp 
ACL-7 TGTTCGAAGCCAAGGCC 903bp 
ACL-6 deletion GAA TAC CTG GCC CTG CAA 690bp 
Primer on vector ACCATGATTACGCCAAGC 
  
5-2-3. Production and analysis of the metabolites in mutants  
L. enzymogenes OH11 and its ACL mutants were grown in 1/10 TSB for 1 day, and 
an aliquot of 200 µl was spread on the solid NYGA fermentation medium 
(Bacteriological Peptone, 5 g/L; yeast extract, 3 g/L; glycerol, 20 g/L, and agar 15 
g/L). The plates were incubated at 28 °C for 2 days. To extract the metabolites, the 
solid culture broth was collected and extracted with methanol. The organic phase was 
dried with a rotavapor (Buchi, Rotavapor R-200) to afford the crude extract. The 
extract was dissolved in 2 ml methanol containing 0.05% TFA. A 20 µl aliquot of 
each extracts was analyzed by HPLC (1220 Infinity LC, Agilent Technologies) using 
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a reversed-phase column (Cosmosil 5C18-AR-II, 4.6 ID × 250 mm). Water/0.01M 
TFA (solvent A) and acetonitrile/methanol = 1:1 (solvent B) were used as the mobile 
phases with a flow rate of 1.0 mL/min. The HPLC program was as follows: 57% B in 
A in the first 5 min, 57–100% B in 5–32 min, 100% B in 32–40 min, back to 57% B 
at 41 min, and maintained to 48 min. The metabolites were detected at 280 nm on a 
UV detector. LCQ-MS was used to verify the mass of the peak of WAP-8294A2 and 
analogues. 
5-2-4. Generation of gene deletion mutants 
To construct the ACL-6 in-frame deletion vector, primer extension PCR reactions 
were performed to generate a 705-bp fragment of ACL-6 upstream and downstream 
regions. This deleted the whole ACL-6 gene. The primers used for these experiments 
are listed in Table 5-1. The PCR amplified fragment was then cloned into the conjugal 
vector pJQ200SK as an XhoI/BamHI fragment to produce pJQ200SK-ACL-6. To 
conjugally transfer pJQ200SK-ACL-6 into L. enzymogenes strain OH11, the 
procedure was identical to the previously described. The correct single crossover 
mutant was confirmed by diagnostic PCR. The single colonies identified from single 
crossover were cultured in the presence of 5% (W/V) sucrose to select for the loss of 
the vector through a second homologous recombination. The single crossover mutants 
were grown in 1/10 tryptic soy broth (TSB) medium for 14 hours. Then the individual 
cultures were re-inoculated into 1/10 TSB (with 1:100 ratio) containing 5% sucrose 
and 25 µg/ml kanamycin medium. Aliquots (50 µl) were taken out every 3 hours from 
this liquid culture and spread onto 1/10 TSA plates (5% sucrose, 25 µg/ml 
kanamycin). Single colonies were picked up from the plates and continued to grow in 
1/10 TSB (5% sucrose, 25 µg/ml kanamycin) liquid medium for another 2-5 days. To 
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confirm the double crossover mutant, the diagnostic PCR was performed using 
genomic DNA extracted from the single colonies as template.  
5-2-5. Construction of ACL-6 overexpression and complementation mutants 
The coding region of ACL-6 was amplified, using primers ACL-6-up and 
ACL-6-down (Table 5-1), from the genomic DNA of the wild type strain. The PCR 
product was digested with BamHI/XhoI and cloned into the same sites of the vectors 
pHmgA to generate pHmgA-ACL-6137. This vector included one homologous region 
of hmgA gene, and the plasmid containing the ACL-6 gene is therefore expected to 
integrate into the hmgA gene in OH11 genome by homologous recombination. The 
hmgA gene is predicted to encode a homogentisate 1,2-dioxygenase, which catalyzes 
the oxidative cleavage of the aromatic ring of tyrosine/phenylalanine, which is a key 
step in aromatic amino acid degradation pathway. The disruption of hmgA gene 
blocks the oxidative cleavage reaction and leads to the accumulation of homogentisate, 
exhibiting black color in the mutant organisms and allowing for easy selection of the 
single-crossover mutants into whose genomes the construct has been integrated141, 142. 
In each the constructs, the coding region of ACL-6 was placed downstream from the 
respective promoter. The constructs were validated and transferred into L. 
enzymogenes OH11 and ACL-6 deletion mutant by conjugation. The black colored 
colonies were selected and verified by diagnostic PCR138, 139. 
5-2-6. Supplementation of ACL-6 mutant with 3-hydroxy-7-methyloctanoic acyl 
SNAC 
ACL-6 mutant was grown in 1/10 TSB for 1 day, and an aliquot of 1 mL was 
transferred to each of two 1 L NYGB liquid cultures. The culture was fed with the 
fatty acyl-SNAC dissolved in DMSO under pulse feeding on 2 following days (0.12 
122	  	  
	  
mmol/L and 0.06 mmol/L)140. Metabolites were extracted from the supernatant with 
ethyl acetate: methanol: acetic acid = 80: 15: 5. The organic phase was dried with a 
rotavapor (Buchi, Rotavapor R-200) to afford the crude extract. The extract was 
dissolved in 2 ml methanol containing 0.05% TFA. A 20 µl aliquot of each 
extracts was analyzed by HPLC and MS as described above. 
5-2-7. Expression of ACL1-7 genes and purification of the proteins 
To construct the expression vectors for the ACLs, genes fragments from all seven 
ACL genes were amplified by PCR using Taq DNA polymerase with genomic DNA 
extracted from L. enzymogenes OH11 as template. The primers are listed in the table 
5-1. The PCR fragment was digested and cloned into pANT841 at the same sites. The 
constructs were sequenced, and the result showed that all the ACL sequences were 
correct. The ACLs were released from pANT841 and cloned into expression vector 
pET28a. To express the ACLs, the pET28a construct was introduced into E. coli 
BL21 (DE3). Single colonies were inoculated in 3 ml of liquid LB medium containing 
kanamycin (50 µg/ml) and incubated in a shaker (250 rpm) at 37 °C overnight. The 
overnight culture was added to 50 ml fresh LB medium and incubated in a shaker 
(250 rpm) at 37 °C until the cell density (OD600) reached 0.6. To induce the 
expression of the ACLs, IPTG (0.1 mM) was added to the culture, and the cells were 
allowed to grow at the same conditions for another 3 h. To prepare the soluble 
fraction, the cells were harvested and resuspended in 2 ml of Tris-HCl buffer (250 
mM NaCl, 100 mM LiCl, 50mM Tris). The cell suspension was supplemented with 
lysozyme (1 mg/ml) and sonicated five times on ice. The soluble fraction of protein 
extracts was loaded onto a Ni-NTA column, which was previously calibrated with 
Tris buffer containing 10 mM imidazole. The column was washed three times with 
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the buffer containing 20 mM imidazole, and the His6-tagged protein was eluted twice 
with 200 µl of Tris buffer containing 250 mM imidazole (Figure 5-11). The fractions 
containing pure ACLs were collected and dialyzed against Tris buffer containing 15 % 
glycerol. 
5-2-8. In vitro assay of acyl-CoA ligase activity 
Enzymatic reactions to generate fatty acyl-CoA were set up using the following 
conditions: 10 µM ACLs, 0.2 mM CoA, 10 mM ATP, 20 µM fatty acid in DMSO, 5 
mM MgCl2, 0.2% (w/v) Triton, 200 µM DTT, and 100 mM Tris-HCl pH 7.8. All 
reactions were incubated at 30 °C overnight. Samples were analyzed by HPLC (1220 
Infinity LC, Agilent Technologies) using a reversed-phase column (Phenomen-ex, 4.6 
ID × 150 mm). Water/25 mM ammonium acetate/0.5% acetic acid (solvent A) and 
acetonitrile/0.5% acetic acid (solvent B) were used as the mobile phases with a flow 
rate of 1.0 mL/min. The HPLC program was as follows: 10% B in A in the first 3 min, 
10-90% B in 3–15 min, 90% B in 15-25 min, back to 10% B at 26 min, and 
maintained to 30 min141. The metabolites were detected at 260 nm on a UV detector. 
MS (Finnigan mat, LCQ) was used to verify the mass of the peak of products. To 
further elucidate the structure of the product, Agilent LC-1200 (Santa Clara, CA) 
connected to a 2.1× 100 mm Symmetry ODS column from Waters (Milford, MA) and 
a Triple Quadrupole Mass Spectrometer model 4000 QTrap from ABSciex 
(Framingham, MA) operating in either single quadrupole (Q1), enhanced mass 
spectrum (EMS), MS/MS or multiple reaction monitoring (MRM) modes were 
used.  The samples were injected onto the column and a gradient from 98% mobile 
phase A (0.1% formic acid in water, J.T. Baker) to 60% B (0.1% formic acid in 
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acetonitrile, Acros Organics) was run over 15 minutes, followed by 5 minutes of 98% 
B and 5 min of 98 % A, all at a flow rate of 0.25 mL/min. 
5-2-9. Kinetic analysis of acyl-CoA ligase activity 
The EnzChek Pyrophosphate Assay Kit was used to measure the enzymatic activities 
of ACLs.  
(A) 
 
(B) 
 
(C) 
 
 
 
 
 
Figure 5-5. Enzymatic conversion of A: fatty acids to fatty acyl-S-CoA by ACLs, 
releasing a pyrophosphate group. B: A pyrophosphate group to 2 phosphate groups 
via the hydrolysis of inorganic pyrophosphatase. C: 2-amino-6-mercapto- 
7-methyl-purine ribonucleoside (MESG) to ribose 1-phosphate and 2-amino- 
6-mercapto-7-methylpurine by purine ribonucleoside phosphorylase (PNP).  
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A standard curve for the pyrophosphate assay was generated using the pyrophosphate 
standard as a source of PPi. The linear range of the assay for PPi extends from 1 µM 
to about 75 µM. The standard 1 mL reaction mixture contains: 730 µL - x µL dH2O 
(to create a final volume of 1.0 mL), 50 µL 20 × reaction buffer, 200 µL MESG 
substrate solution, various µL-volumes of sample to be analyzed for pyrophosphate 
content, 10 µL purine nucleoside phosphorylase (1 U), 10 µL inorganic 
pyrophosphatase (0.03 U). In this reaction, the analytical sample volumes were 0, 10, 
20, 40, 80, 120 and 150 µL, respectively, giving concentrations of 0, 5, 10, 20, 40, 60 
and 75 µM, respectively. The reaction solutions were mixed well and incubated for 
30-60 minutes at 22 °C. The absorbance at 360 nm was recorded over this time period. 
The background absorbance determined for the no-pyrophosphate control was 
subtracted from each sample before plotting the curve. A standard curve (y = 0.0156x 
+ 0.0004, R² = 0.99603) for the pyrophosphate assay was generated using the 
pyrophosphate standard as a source of PPi.  
The proper ACL 1-7 protein concentrations in the reaction were determined 
spectrophotometrically by varying protein concentration between 1 µM to 15 µM. 
Initial kinetic parameters (kcat and KM) were obtained by saturating with two 
substrates and varying the concentration of a third substrate142. For fatty acid kinetic 
constant determination, both CoA (400 µM) and ATP (400 µM) were kept at fixed 
saturating concentrations, and fatty acid (1 µM–2 mM) was kept at variable 
concentrations. Individual substrate saturation kinetic data were fitted to Equation 1, 
                 （Equation 1） v =
Vmax [S]
Km + [S]
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where v is the reaction rate, Vmax is the maximal velocity, [S] is the substrate 
concentration, and KM is the Michaelis-Menten constant. 
To measure the activity of acyl-CoA ligase, the following reagents were combined in 
0.1 mL reaction volumes: 0.4 mM ATP, 0.4 mM CoA, 0.4 mM free fatty acids in 
DMSO, 0.2 mM MESG, 1 U purine nucleoside phosphorylase, 0.01 U 
pyrophosphatase, 1× reaction buffer and various ACLs with final concentration of 15 
µM. After incubating at 22°C for 30 minutes, the absorbance at 360 nm was measured 
and corrected for absorbance at 360 nm of a control reaction which the ACL protein 
was replaced by the purified protein extracted from the pET28a blank vector hosted E. 
coli cell. The substrates being tested are chemically synthesized 
3-hydroxyl-7-methyloctanoic acid (which corresponded to WAP-8294A2) and 
3-hydroxyl-octanoic acid (which corresponded to WAP-8294A1). The kinetics of 
ACL 1-7 were determined by initial velocity experiments using the coupled assay. 
These data were globally fitted to Michaelis-Menten Equation, yielding Km values for 
the substrates.  
 
5-3. Results and discussion 
In the previous study, an ACL-coding gene (accession number JN596953) present in 
one of the uncharacterized PKS/NRPS clusters within the genome of L.e. OH11 was 
disrupted to test if the WAP assembly could use an ACL in other metabolic 
pathways110. This mutant showed a partial loss of the antibacterial activity and 
produced approximately 50% of the WAP-8492A yield of the wild type. This result 
suggests that the WAP-8492A biosynthetic pathway is likely to recruit an ACL from 
other pathways. This type of in trans ACLs generally exhibit a broad specificity and 
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functional redundancy, which is consistent with the fact that all WAP-8492A 
compounds have the same amino acid composition but vary in the length of the fatty 
acid side chain.  
5-3-1. Generation of gene disruption mutants  
We have identified 14 putative ACL genes in the genome, among which 7 are 
associated with secondary metabolism. To test if the WAP assembly could use an 
ACL in other metabolic pathways, we disrupted the seven ACL encoding ORFs. The 
HPLC and MS analysis showed that the individual disruptions of the seven ACLs 
failed to eliminate the production of WAPs. Although the mutants showed varied 
yields of WAPs, the ACL-6 disruption mutant gave the lowest yield (Figure 5-7), 
making this putative ACL the best candidate for WAP’s “normal” ACL. In our 
following experiments we focused our attention on this putative ACL enzyme. 
 
 
 
   (a)             (b)                        (c)            (d) 
Figure 5-6. ACL1-6 disruption mutants diagnostic PCR: 
a: Diagnostic PCR result of ACL-1 and ACL-4 mutants. 
b: Diagnostic PCR result of ACL-2, ACL-3, and ACL-5 mutants. 
c: Diagnostic PCR result of ACL-6 mutants. 
d: Diagnostic PCR result of ACL-7 mutants. 
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Figure 5-7. WAP standard and metabolite profiles of Lysobacter enzymogenes OH11 
wild type, ΔACL 1-7: ACL disruption mutants 1-7. 
 
5-3-2. Synthesis of 3-hydroxy fatty acids and 3-hydroxy fatty acyl SNAC  
(note: I acknowledge Andrew Olson for preparing the 3-hydroxy fatty acids and 
3-hydroxy fatty acyl SNAC) 
 VWD1 A, Wavelength=280 nm (HAOTONG\STANDARD 2013-06-03 09-34-17.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-1 2013-06-27 10-28-50.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-2 2013-06-03 10-24-07.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-3 2013-06-03 11-13-32.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-4 2013-06-03 12-04-24.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-5 2013-06-03 12-56-50.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-6 2013-06-03 13-45-25.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\ACL-7 2013-06-03 14-34-19.D)
 VWD1 A, Wavelength=280 nm (HAOTONG\OH11 WT 2013-06-27 14-18-20.D)
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To generate the initial carbon backbone, we generated the dianion of methyl 
acetoacetate with LDA; subsequent alkylation with the aliphatic halide provide the 
initial carbon skeleton in roughly 20-50% yields (1a-c)143. A subsequent asymmetric 
reduction of the β-keto ester with borane dimethyl sulfide complex in the presence of 
CBS-oxazaborolidine provides the β-hydroxy ester in 20-40% yield (2a-c) with a 
90-92% enantiomeric excess of R isomer144. Hydrolysis to the carboxylic acid from 
the methyl ester was accomplished in almost quantitative yield (3a-c) by the addition 
of LiOH. Selective formation of a thioester in the presence of the free alcohol is 
accomplished through carbodiimide-mediated coupling with N-acetylcysteamine 
(SNAC) by way of DCC with catalytic amount of DMAP to provide the 3-hydroxy 
thioester in 70-80% yields (4a-c).  
 
 
 
 
 
Figure 5-8. Chemical synthesis of 3-hydroxy fatty acids and 3-hydroxy fatty 
acyl-SNAC. 
 
5-3-3. Construction of ACL-6 in-frame deletion mutants and complementation 
by feeding experiments 
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To eliminate any possibility of polar effects caused by insertion of the conjugal vector 
into the ACL gene, we also generated in-frame deletion mutants for ACL-6 gene 
(Figure 5-9). WAP production of this mutant strain was monitored by HPLC-MS. 
Similar to the ACL-6 disruption mutant, the WAP A2 production in the in-frame 
deletion mutant was diminished to less than 10% compared with the wild type, thus 
confirming the gene disruption results shown above. 
Next, we attempted to chemically restore WAP-8294A2 biosynthesis in the ACL-6 
mutant by adding the CoA surrogate, the N-acetylcysteamine thioester (SNAC) of 
3-hydroxy-7-methyloctanoic acid. After feeding the synthetic 3-hydroxy 
7-methyloctanoic acyl-SNAC into the culture by pulse feeding on two following days, 
the WAP production was successfully restored (Figure 5-10). This result clearly 
showed that ACL-6 is involved in starter unit activation, but does not participate in 
NRPS priming; the NRPS could probably be primed by any acyl thioester carrying the 
3-hydroxy functional group. Interestingly, an ACL-6 overexpression mutant didn’t 
increase the yield to any significant extent compared with the wild type.  
 
 
 
Figure 5-9. Diagnostic PCR result of ACL-6 double-crossover mutants (ACL-6 
deletion). 
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Figure 5-10. Metabolic profiles of a) Lysobacter enzymogenes OH11 ACL-6 in-frame 
deletion mutant (ΔACL-6), b) ΔACL-6 mutant supplemented with 
3-hydroxy-7-methyloctanoic acyl-SNAC, c) WAP-8294 A2 standard. 
 
5-3-4. ACLs expression and purification  
To identify the relevant ACL gene(s) and reveal the molecular basis for acyl chain 
diversity, we also expressed the seven putative ACL genes heterologously and tested 
the substrate specificity of the enzymes. Seven ACL genes were amplified and cloned 
into expression vector pET28a. After DNA verification by sequencing, heterologous 
expression in E. coli BL21 yielded satisfactory quantities of soluble ACL 1-7 proteins. 
As judged by SDS-PAGE, the observed ACL 1-7 molecular masses were consistent 
with the predicted molecular weights (58.7, 58.8, 60.4, 59.8, 61.0, 47.2, 58.6 kDa) 
calculated from the amino acid sequence, including the His6tag (Figure 5-11).  
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Figure 5-11. Purified ACL1-7 proteins with the expected size shown on SDS-PAGE. 
1P-7P: precipitate portion of ACL 1-7 protein extracts. 
 
5-3-5. In vitro assay of acyl-CoA ligase activity  
 
 
 
 
 
 
 
 
Figure 5-12. Reaction scheme of the activation of 3-hydroxy-7-methyloctanoic acid 
by ACLs and the structure of 3-hydroxy-7-methyloctanoic acyl-CoA. 
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ACL-6 reaction system. This peak was collected and subjected to MS, giving a mass 
identical to that of 3-hydroxy-7-methyloctanoic acyl-CoA (m/z =924.23) (Figure 
5-14). Tandem mass spectrometer fragmented the compound into product ions, and 
both the precursor ion (m/z = 924.90) and product ion (m/z = 417.20) were detected, 
while the control reaction (w/o enzyme) only exhibited the precursor and product ions 
of CoA (m/z=768.12 and m/z =261.20) (Figure 15-18). The result shows that ACL-6 
catalyzes the thioester formation with CoA. ACL-3 and ACL-5 also showed some 
activity, but the product was so minute that the peak could not be detected by HPLC. 
The target mass could only be detected by  MS, suggesting that the substrate 
selectivity and activity of these ACLs in vitro are weak toward the 3-hydroxy acyl 
thioester substrate. Additionally, activity of enzymes ACL1-7 against 
3-hydroxy-octanoic acid, which is supposed to be the fatty acid substrate of 
WAP-8294A1, was tested. HPLC and MS data showed that the fatty acid substrate of 
WAP-8294A1 is favored by ACL-5 instead of ACL-6, indicating that ACL-6 has 
some specificity toward 3-hydroxy 7-methyloctanoic acid (Figure 5-13). 
Both in vitro and in vivo assay verify that ACL-6 is the most likely enzyme that 
activates 3-hydroxy 7-methyloctanoic acid into WAP assembly line. 
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Figure 5-13. HPLC and MS analysis of the activation of 3-hydroxyl-octanoic acid by 
ACL-5 in vitro. The ESI-MS signals were measured in positive single ion mode. 
 
 
 
 
 
 
 
 
 
Figure 5-14. HPLC and MS analysis of the activation of 3-hydroxyl-7-methyl acid by 
ACL6 in vitro. The ESI-MS signals were measured in positive single ion mode. 
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Figure 5-15. LC-MS (+) of the enzymatic reaction. a: Extracted Ion Chromatogram 
(XIC) of the enzymatic reaction (3-hydroxyl-7-methyloctanoic acyl-CoA with 
m/z=923.23). b: Mass Spectrum of the selected product peak. 
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Figure 5-16. MS/MS (+) of the control reaction a: Total Ion Chromatogram (TIC) of 
the control reaction b: MS-MS Spectrum of the selected peak showing expected 
fragments for CoA. 
Fragmentation pattern: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-17. MS/MS (+) of the enzymatic reaction. a: Total Ion Chromatogram of the 
enzyme reaction. b: MS-MS Spectrum of the selected peak showing that expected 
fragments for product. 
Fragmentation pattern: 
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Figure 5-18. Multiple Reaction Monitoring (MRM) Chromatogram of Enzyme 
Reaction. a: MRM Chromatogram of monitoring Q1(+) (the first mass analyzer) 
m/z=924.23 and Q3 (+) (the third mass analyzer) m/z =417.23, confirming the identity 
of the product formed. b: MRM Chromatogram of monitoring Q1 (+)m/z =768.2 and 
Q3 (+) m/z =261.0, showing that there is no peak for CoA, indicating that the 
substrates are consumed by the reaction. 
 
5-3-6. Kinetic analysis of acyl-CoA ligase activity  
To quantify the enzymatic activity of ACL-6, we performed the initial velocity studies 
142. The substrate selectivity was also evaluated by the kinetics assay using EnzChek 
Pyrophosphate Assay Kit. The inorganic pyrophosphatase in this kit catalyzes 
conversion of PPi into two equivalents of Pi. The Pi is then consumed by the 
2-amino-6-mercapto-7-methyl-purine ribonucleoside (MESG) by purine 
ribonucleoside phosphorylase (PNP) and the product 2-amino-6-mercapto-7-methyl 
purine is detected by an increase in absorbance at 360 nm (Figure 5-5). Thus the 
(a) 
(b) 
138	  	  
	  
EnzChek Pyrophosphate Assay Kit can be used for the quantitation of PPi in solution 
or for the continuous determination of PPi released in enzymatic reactions145, 146. To 
measure the activity of ACLs, the enzymes were incubated with free fatty acid, ATP, 
CoA and the coupled reaction system provided by the kit as described above. The 
kinetic mechanisms of ACL 1-7 were determined by initial velocity experiments 
using the coupled assay. These data were globally fitted to Michaelis-Menten 
Equation, yielding KM values for 3-hydroxyloctanoic acid. The data and graphs 
suggested that substrate 3-hydroxyloctanoic acid is favored by ACL-5 (Km=15.001 ± 
1.894 µM, kcat=0.0198 ± 0.0003 min-1), while 3-hydroxyl-7-methyloctanoic acid is 
favored by ACL-6 (Km= 4.900 ± 0.0810 µM, kcat= 0.326 ± 0.005 min-1), but not 
completely ignored by the other ACLs. This is consistent with the idea that in trans 
ACLs generally exhibit a broad specificity and are functionally redundant (Table 5-2 
a-b). Saturation kinetics was not achievable for ACL-2 at concentrations less than 
10 µM. No steady signal was detected in the enzyme-free control reactions, showing 
that the data obtained resulted from the enzymatic activities of ACLs. This is 
consistent with the in vitro and in vivo data that the ACL-6 is the corresponding ligase 
of 3-hydroxy 7-methyloctanoic acid and CoA, while ACL-5 selectively catalyzes the 
ligation of 3-hydroxy octanoic acid with CoA. Although these ACLs differ in KM to a 
large extent, both kcat and vmax were relatively small. The slow reaction rates might 
explain the very low yield of WAPs in the microorganism. 
(A) 
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 (F) 
 
 
 
 
 
 
Figure 5-19. Kinetic mechanisms of ACL 1-7 (except ACL-2) using 
3-hydroxyl-7-methyloctanoic acid as substrate. A-F: ACL1, 3, 4, 5, 6, 7. Left: initial 
rate curve. Right: Michealis-Menten equation fitted curve.  
 
Table 5-2. a: Kinetic parameters for ACL 1-7 against 3-hydroxy-octanoic acid 
 
 KM (µM)  vmax (µM/min) kcat (min-1) 
ACL-1 68.88 ± 20.67  0.1671 ± 0.0075 0.0111 ± 0.0005 
ACL-3 62.65 ± 1.29  0.2248 ± 0.0053 0.0149 ± 0.0003 
ACL-4 3.41 ± 0.99 0.1845 ± 0.0066 0.0123 ± 0.0004 
ACL-5 15.00 ± 1.89  0.2983 ± 0.0044 0.0198 ± 0.0003 
ACL-6 342.07 ± 16.58  0.0405 ± 0.0081 0.0027 ± 0.0005 
ACL-7 15.49 ± 1.05 0.0864 ± 0.0039 0.0057 ± 0.0002 
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Vmax 1.000 1.923 1.640 1.050 1.193 1.231 1.084 1.301
R^2 0.995 0.944 0.995 0.969 0.899 0.989 0.992 0.994
Vmax Points = 145
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b: Kinetic parameters for ACL 1-7 against 3-hydroxy 7-methyloctanoic acid 
 
 KM (uM)  vmax (µM/min) kcat (min-1) 
ACL-1 70.24 ± 12.43  0.2420 ± 0.0065  0.0161 ± 0.0004 
ACL-3 6.12 ± 1.67  0.3148 ± 0.0073  0.0209 ± 0.0004 
ACL-4 511.76 ± 379.39  0.6342 ± 0.0859  0.0422 ± 0.0057 
ACL-5 49.98 ± 11.87  0.9535 ± 0.0397  0.0635 ± 0.0026 
ACL-6 5.84 ± 1.28  4.9006 ± 0.0810  0.3267 ± 0.0054 
ACL-7*    
 
*: ACL7 does not show distinct activity toward this substrate, thus the kinetics 
parameters could not be obtained. 
*: Saturation kinetics was not achievable for ACL-2 at concentrations less than 
10 µM. 
 
5-4. Summary and final remarks 
WAP-8294As are cyclic lipodepsipeptides with potent antibacterial activity. Although 
many lipopeptide antibiotics are known, including daptomycin (Cubicin), 
WAP-8294As exhibit exceptionally potent activities against MRSA and VRSA (ED50 
is 14 times higher than that of vancomycin). The fact that WAP-8294A2 reached the 
Phase-I/II clinical studies testifies to its promise. Thus, study and engineering of 
WAPs biosynthetic gene cluster to produce various WAPs analogues represent a 
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valuable new opportunity to generate new antibiotics. In the previous study,110 we 
identified a total of 45 domains from the two NRPS genes within the WAPS cluster, 
representing one of the largest NRPS systems.  
The N-terminus of WAPs is acylated with a fatty acid side chain, which is a common 
feature found in other cyclic lipopeptides, such as surfactin, amphi-enterobactin130, 
daptomycin, fengycin147 and CDA148. When analyzing the C domain phylogeny of 
this type of NRPS, the N-terminus C domains present in the biosynthetic gene cluster 
of the lipopeptides listed above did not cluster with the known C domain subtypes, 
not even with the C domains downstream in the same assembly line. This N-terminus 
C domain is supposed to serve as an acceptor for a fatty acid, which is activated by 
ACLs149-151. In the case of surfactin biosynthesis, there are four putative ACL genes in 
the B. subtilis genome, two of which have the ability to catalyze the ligation of 
3-hydroxyfatty acids and CoA152. Disruption of each of the four ACL could not 
eliminate the production of surfactin. Similarly, a disruption of an ACL gene 
(accession number JN596953) found in the genome of L. enzymogenes OH11 lowered 
the antibacterial activity and the yield of WAP-8294A2, suggesting a broad 
specificity and redundancy of these ACLs110. This is consistent with the fact that all 
WAP-8492A compounds have the same amino acid composition but vary in the 
length of the fatty acid side chain. 
To further prove this feature and discover the most essential ACLs for fatty acyl 
priming in WAP biosynthesis, we constructed seven ACL disruption mutants. None 
of these mutants eliminates WAP production completely, suggesting that the 
3-hydroxy fatty acid substrates can be activated by various ACLs. Among the 7 
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mutants, the ACL-6 mutant had the lowest yield of WAPs, thus became an important 
candidate in our investigation.  
The ACL-6 deletion mutant was constructed to eliminate any possibility of polar 
effects caused by gene disruption, which inserts a large plasmid into the genome. We 
also constructed complementation and overexpression vectors to verify the ACL-6 
activity, but were not able to obtain the ACL-6 complementary mutant. Instead, we 
used a chemically synthesized CoA surrogate, 3-hydroxy-7-methyloctanoic acid 
SNAC, in a feeding experiment to verify the activity. The subsequent restoration 
WAPs production supported that ACL-6 is required in WAP fatty acid substrate 
activation, but not NRPS priming. It also suggested that feeding the ΔACL-6 mutant 
with different side chain substrates to generate novel WAP analogues is possible.  
We were able to express the seven ACL genes in E. coli and purify the enzymes. The 
kinetic data from in vitro studies revealed that ACL-6 is the most likely enzyme 
involved in WAP-8294A2 synthesis, while ACL-5 is the most likely enzyme involved 
in activating the acyl substrate of WAP-8294A1. Based on the results presented in 
this study, we propose the mechanism shown in Figure 5-20 for the initiation of the 
biosynthesis of WAPs.  
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Figure 5-20. Proposed lipidation reaction during WAP biosynthesis. The fatty acid is 
activated by ACLs and then recognized by the donor site of C domain, which 
catalyzes the nucleophilic attack of the amino group of the PCP-bound serine on the 
carbonyl of fatty acyl-CoA. 
 
The understanding of the activation mechanisms of the fatty acyl portion of the WAPs 
obtained in this study can be used to guide future biosynthetic engineering efforts. 
Fatty acid moieties have strong influence on the activity and properties of natural 
products. The final goal of this study is to generate a small family of WAP-8294A2 
analogues with optimal structure-activity features (such as solubility verses activity 
by varying the fatty acid chain length and replacing certain amino acid residues) by 
feeding the wild type as well as the mutants with fatty acids with different chain 
lengths and various amino acids to direct the biosynthesis toward an optimized 
compound. It should also allow transfer of such logic to the discovery of new 
bioactive NPs from other Lysobacter species and allow optimization of the yield, 
structure, and activity of the Lysobacter anti-infectives.  
An important task for the future is to understand the NRPS initiation in WAPs 
biosynthesis by investigating the activity of the first NRPS module (C-Aser-PCP) in 
vitro. Although most C domain exhibits a greater selectivity towards the amino acid 
activated by the A domain within the same module compared with the intermediate in 
upstream modules153, 154, it’s incorrect to draw the conclusion that the fatty acyl 
substrate selectivity is only determined by ACLs. If the first C domain catalyzes the 
transfer of activated 3-hydroxy fatty acid at its donor site to the peptidyl carrier 
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protein (PCP) bound amino acid serine, the mechanism of lipoinitiation of WAPs 
could be explored using the purified C-Aser-PCP.  
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